Protac compound targeting estrogen receptor, preparation method therefor, and use thereof
Through the PROTAC compound targeting estrogen receptors, the ubiquitin ligase system is used to induce estrogen receptor degradation, which solves the problems of limited effectiveness and drug resistance of existing breast cancer treatments in patients with ER mutant types, and achieves the ER-positive breasts Effective inhibition and safety of cancer are improved.
Patent Information
- Application Number
- PCT/CN2024/095380
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-05-26
- Publication Date
- 2024-12-05
AI Technical Summary
The existing breast cancer treatment methods are limited in effect on ER-positive breast cancer, especially patients with ER mutant, and have problems with drug resistance and side effects, so more effective and safe treatment methods are needed.
Develop a PROTAC compound targeting estrogen receptors. By inducing the degradation of the target protein, the specific structure of the compound of formula (I), the ubiquitin ligase ligand is used to recruit E3 ligase to form the target protein-PROTAC-E3 ubiquitin The ligase ternary complex marks the target protein ubiquitinated and degraded by the proteasome, thereby reducing the expression and activity of estrogen receptors.
This compound can effectively inhibit the growth of ER-positive breast cancer cells at low concentrations, showing good anti-tumor activity and high safety in patients with endocrine therapy resistant, expanding the range of therapeutic targets and reducing toxic side effects .
Smart Images

Figure CN2024095380_05122024_PF_FP_ABST
Abstract
Description
A PROTAC compound targeting estrogen receptor and its preparation method and use Technical Field
[0001] The present application relates to a PROTAC compound that targets estrogen receptor (ER) protein hydrolysis, a preparation method thereof, and a method for treating or preventing diseases mediated by estrogen receptor protein, such as breast cancer, ovarian cancer, etc., belonging to the field of biomedicine. Background Art
[0002] PROTAC stands for protein degradation targeted chimera, which uses the naturally occurring protein cleanup system in human cells - the ubiquitin (UPS) - proteasome system to induce target protein degradation, selectively and efficiently degrade and remove pathogenic proteins. It is a new type of targeted protein degradation engineering technology. Ubiquitin is a small protein present in all eukaryotes, composed of 76 amino acids and a molecular weight of approximately 8.45kDa. The main function of ubiquitin is to mark proteins that need to be broken down. When ubiquitin is attached to proteins and marks them as defective or damaged proteins, these proteins will be recognized and transported to the proteasome for degradation, achieving protein balance within the cell.
[0003] Most small molecule drugs currently used in clinical practice use an "occupancy-driven" mode of action to inhibit protein function and thus play a role in treating diseases. Unlike traditional small molecule inhibitors and antagonists, PROTAC has rapidly developed in recent years as a new approach to new drug development due to its ability to induce the degradation of pathogenic target proteins. PROTAC is a heterobifunctional molecule composed of two small molecule ligands, generally consisting of three parts: a targeting protein ligand, an E3 ubiquitin ligase ligand, and a linker of appropriate length. When the PROTAC molecule enters the cell, the targeting protein ligand in its structure can specifically bind to the target protein, while the E3 ubiquitin ligase (such as cereblon, CRBN) ligand at the other end can recruit the E3 ligase, thereby forming a stable target protein-PROTAC-E3 ubiquitin ligase ternary complex. After the target protein is ubiquitinated, the ubiquitinated protein is recognized and degraded by the proteasome 26S in the cell. Traditional small molecules and antibodies work by inhibiting target protein function through an "occupancy-driven" mode of action. This mode of action requires high concentrations of the inhibitor or monoclonal antibody to occupy the target's active site and block downstream signaling pathways. PROTACs, on the other hand, operate through an "event-driven" model, capable of binding anywhere on the target protein without high affinity to induce degradation. Therefore, PROTACs can target proteins with smooth surfaces lacking small molecule binding sites. 80% of pathogenic proteins in human cells lack active sites suitable for traditional small molecule binding, meaning many targets undruggable by small molecules are potentially amenable to PROTAC technology. Once a PROTAC mediates the formation of a ternary complex and ubiquitinates the target protein, it can theoretically be recycled and reused. Therefore, a catalytic dose is sufficient, and lower dosing concentrations minimize toxic side effects, resulting in a higher safety profile for PROTAC drugs. Furthermore, PROTACs can induce degradation of proteins lacking active sites, such as scaffold proteins, as long as they bind, significantly expanding their target range. To date, over 100 proteins have been successfully degraded, including some considered undruggable targets. Since the ubiquitin-mediated degradation pathway occurs within cells, small molecule PROTACs currently focus on attacking intracellular targets, including cytoplasmic proteins and nuclear proteins.
[0004] With the extensive and in-depth research on PROTAC, there have been more and more reports on the widespread use of PROTAC in anti-tumor research in recent years, such as in the following journals (for example: Crews et al., Curr Opin Chem Biol. 2019; 50: 111-119; Xu et al., Eur J Med Chem. 2022; 235: 114290; Zou et al., Eur J Med Chem. 2021; 226: 113849; Qin et al., Front Pharmacol, 2021; 12: 692574; Song et al., J Hematol Oncol. 2020; 13(1): 50; Crews et al., Cancer Res. 2019; 79(1): 251-262; Rao et al., ACS Med Chem Lett. 2020; 11(3): 237-240; Wang et al., J Med Chem.2019;62(21):9471-9487;Crews et al., Pharmacol Ther.2017Jun;174:138-144.) and patents (e.g., CN113248473, CN112812100, CN109761970, US2019019419, US20190151295, US20200129627, US20180125821, US20160045607, CN107428734, WO2017197046, WO2002020740, WO2017197056, WO2017117474, WO2017197055).
[0005] ER + HER -Breast cancer is defined as estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative. This type of breast cancer is the most common type of breast cancer, accounting for 65% of breast cancer cases in women under 50 years of age and 75% of breast cancer cases in women 50 years of age and older. Estrogen (E2) is a class of steroid compounds with a wide range of biological activities, including estradiol, estriol, and estrogen. It plays an important role in maintaining physiological functions such as reproductive system development and bone maturation. The estrogen receptor (ER) is a member of the steroid hormone receptor superfamily and a ligand-dependent transcription factor. Estrogen binds to the ER, stimulating receptor-regulated transcription, thereby promoting tumor cell growth and proliferation. Hormonal therapies for ER-positive breast cancer can reduce estrogen production, interrupt ER signaling, degrade ER, or alter ER-regulated signaling or proliferation pathways. Estrogen production and ER signaling are drivers of breast cancer development, growth, proliferation, and metastasis, and are targets for effective drugs for early-stage breast cancer. New targeted therapies used in combination with endocrine therapy can improve outcomes in advanced breast cancer and inhibit the activity of key pathways involved in cell growth, proliferation, and metastasis. Mutations in the ER gene ESR1 (ESR1mut) or epigenetic changes in c-myc, cyclin D, and epidermal growth factor receptor (EGFR) are associated with resistance to endocrine therapy.
[0006] Epidemiological studies have found that ERα expression is higher in breast tissue from breast cancer patients than in breast tissue from patients without breast cancer. Furthermore, ERα expression is higher in the mammary epithelium of people with a high risk of breast cancer than in those with a low risk of breast cancer. Perhaps the most important factor in the development and progression of breast cancer is not the level of ERα or ERβ, but the ratio of ERα to ERβ.
[0007] Breast cancer is the most common malignancy affecting women. In 2020, the latest data from the American Cancer Society showed that more than 250,000 cases of breast cancer were diagnosed in the United States each year, of which nearly 80% were estrogen receptor positive (ER +). Endocrine therapy for breast cancer mainly exerts its anti-tumor effect by blocking the binding of estrogen to tumor cells and inhibiting estrogen production. Estrogen acts as an endocrine growth factor for breast cancer, and estrogen deprivation is a recognized treatment for advanced breast cancer in premenopausal women. The main treatment methods currently include: 1. Oophorectomy is the most economical surgical castration treatment method and the most thorough treatment, but it is somewhat traumatic. Pharmacological ovarian function suppression is another optional method, but a small number of people cannot achieve complete suppression; 2. Aromatase inhibitors can block the estrogen receptor conversion pathway and reduce estrogen levels; 3. Estrogen receptor (ER) antagonists, modulators or degraders can reduce ER expression at the transcript or protein level, reduce estrogen receptor levels, and inhibit the growth of cancer cells. These existing endocrine treatment methods also have problems such as limited treatment range, basically ineffectiveness in patients with mutations, drug resistance, and large side effects. Therefore, clinical treatment still needs to develop more effective and safe treatment methods.
[0008] In 2019, Arvinas' PROTAC drug ARV-471, which targets ER degradation, entered Phase I clinical trials. Preclinical results showed that ARV-471 significantly inhibited tumor growth in multiple ER-dependent breast cancer models. Preliminary data from the Phase I trial showed that ARV-471 exhibited strong anti-tumor activity and a favorable safety profile in patients with ER mutations and those who were refractory to existing endocrine therapy. This marks the first PROTAC drug in the breast cancer field to enter clinical trials.
[0009] Summary of the Invention
[0010] One object of the present application is to provide a novel oral estrogen receptor-targeted protein degrader (PROTAC) compound or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof.
[0011] Another object of the present application is to provide the use of the compound of the present application or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof.
[0012] Specifically, this application involves the following technical solutions:
[0013] In one embodiment, the present application provides a PROTAC compound targeting an estrogen receptor represented by formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof:
[0014] in, Indicates absence, substitution or unsubstituted Substituted or unsubstituted X 4represents N or CRa, and the substituent is selected from halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amine, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl;
[0015] When A does not exist, R 1 is selected from halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl, preferably R 1 Selected from -NH2 or -OH;
[0016] X 1 N or CR 3 ;
[0017] X 2 or X 3 Each independently selected from CH, CR 3 and N;
[0018] R 2 、R 3 Each is independently selected from H, halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl;
[0019] Ra is selected from H, halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl;
[0020] L is selected from the following:
[0021] E3L stands for ubiquitin ligase ligand.
[0022] Preferably, E3L is selected from one of the following:
[0023] Preferably, the compound of the present application is as shown in formula (II):
[0024] Among them, R 4 Selected from halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl.
[0025] Preferably, R 4 It is a halogen.
[0026] Preferably, the compound of the present application is as shown in formula (III):
[0027] Preferably, the compound of the present application is as shown in formula (IV):
[0028] Preferably, L is selected from the following:
[0029] Preferably, X 4 is N.
[0030] Preferably, X 4 is CRa, and Ra is selected from H, halogen and hydroxy.
[0031] Preferably, Ra is H.
[0032] Preferably, X 1 CR 3 , R 3 is H, CH3O or F.
[0033] Preferably, R 3 For H.
[0034] Preferably, X 2 For CH.
[0035] Preferably, X 2 is N.
[0036] Preferably, X 3 For CH.
[0037] Preferably, R 2 For H.
[0038] Preferably, E3L is
[0039] Preferably, the compound of the present application is selected from one of the following:
[0040] The present application also relates to a pharmaceutical composition comprising the above-mentioned compound of the present application, a pharmaceutically acceptable salt, solvate, hydrate, or isomer, and a pharmaceutically acceptable carrier.
[0041] The present application also relates to the use of the above-mentioned compound of the present application or its pharmaceutically acceptable salt, solvate, hydrate, or isomer or the above-mentioned pharmaceutical composition of the present application in treating diseases treated by degrading target proteins bound to targeting ligands.
[0042] Preferably, the disorder is selected from abnormal cell proliferation, cancer, immune disease, diabetes, cardiovascular disease, infectious disease and inflammatory disease.
[0043] Preferably, the cancer is selected from breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, endometriosis, fallopian tube tumors, ovarian tumors, leukemia, skin cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, bladder cancer, intestinal cancer, colon cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer, cervical cancer, pancreatic cancer, gastric cancer, lymphoma, non-Hodgkin's lymphoma, melanoma, myeloproliferative diseases, sarcoma, angiosarcoma, peripheral nerve epithelioma, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, neuroblastoma, gangliocytoma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningiosarcoma, neurofibroma, schwannoma, thyroid cancer, Hodgkin's tumor, Wilms' tumor and teratoma; more preferably selected from breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, fallopian tube tumor and ovarian tumor.
[0044] Preferably, the cancer is selected from breast cancer, endometrial cancer, ovarian cancer, cervical cancer, prostate cancer or endometriosis.
[0045] Preferably, the infectious disease is selected from viral pneumonia, avian influenza, meningitis, gonorrhea, or a disease caused by infection with HIV, HBV, HCV, HSV, HPV, RSV, CMV, Ebola virus, flavivirus, rotavirus, influenza, coronavirus, EBV, drug-resistant virus, RNA virus, DNA virus, adenovirus, poxvirus, picornavirus, togavirus, orthomyxovirus, retrovirus, hepadnavirus, Gram-negative bacteria, Gram-positive bacteria, atypical bacteria, Staphylococcus, Streptococcus, Escherichia coli, Salmonella, Helicobacter pylori, Chlamydiaceae, Mycoplasmaceae, fungi, protozoa, intestinal worms, worms, prions or parasites.
[0046] The present application also relates to the use of the above-mentioned compound of the present application or its pharmaceutically acceptable salt, solvate, hydrate, or isomer or the above-mentioned pharmaceutical composition of the present application in the preparation of a drug for treating a disease by degrading a target protein bound to a targeting ligand.
[0047] Preferably, the disorder is selected from abnormal cell proliferation, cancer, immune disease, diabetes, cardiovascular disease, infectious disease and inflammatory disease.
[0048] Preferably, the cancer is selected from breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, endometriosis, fallopian tube tumors, ovarian tumors, leukemia, skin cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, bladder cancer, intestinal cancer, colon cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer, cervical cancer, pancreatic cancer, gastric cancer, lymphoma, non-Hodgkin's lymphoma, melanoma, myeloproliferative diseases, sarcoma, angiosarcoma, peripheral nerve epithelioma, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, neuroblastoma, gangliocytoma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningiosarcoma, neurofibroma, schwannoma, thyroid cancer, Hodgkin's tumor, Wilms' tumor and teratoma; more preferably selected from breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, fallopian tube tumor and ovarian tumor.
[0049] Preferably, the cancer is selected from breast cancer, endometrial cancer, ovarian cancer, cervical cancer, prostate cancer or endometriosis.
[0050] Preferably, the infectious disease is selected from viral pneumonia, avian influenza, meningitis, gonorrhea, or diseases caused by infection with HIV, HBV, HCV, HSV, HPV, RSV, CMV, Ebola virus, flavivirus, rotavirus, influenza, coronavirus, EBV, drug-resistant virus, RNA virus, DNA virus, adenovirus, poxvirus, picornavirus, togavirus, orthomyxovirus, retrovirus, hepadnavirus, Gram-negative bacteria, Gram-positive bacteria, atypical bacteria, Staphylococcus, Streptococcus, Escherichia coli, Salmonella, Helicobacter pylori, Chlamydiaceae, Mycoplasmaceae, fungi, protozoa, intestinal worms, worms, prions or parasites.
[0051] The present application relates to a method for treating a disease in a subject by degrading a target protein bound to a targeting ligand, comprising administering to the subject an effective amount of the above-mentioned compound of the present application or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof or the above-mentioned pharmaceutical composition of the present application.
[0052] Preferably, the disorder is selected from abnormal cell proliferation, cancer, immune disease, diabetes, cardiovascular disease, infectious disease and inflammatory disease.
[0053] Preferably, the cancer is selected from breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, endometriosis, fallopian tube tumors, ovarian tumors, leukemia, skin cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, bladder cancer, intestinal cancer, colon cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer, cervical cancer, pancreatic cancer, gastric cancer, lymphoma, non-Hodgkin's lymphoma, melanoma, myeloproliferative diseases, sarcoma, angiosarcoma, peripheral nerve epithelioma, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, neuroblastoma, gangliocytoma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningiosarcoma, neurofibroma, schwannoma, thyroid cancer, Hodgkin's tumor, Wilms' tumor and teratoma; more preferably selected from breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, fallopian tube tumor and ovarian tumor.
[0054] Preferably, the cancer is selected from breast cancer, endometrial cancer, ovarian cancer, cervical cancer, prostate cancer or endometriosis.
[0055] Preferably, the infectious disease is selected from viral pneumonia, avian influenza, meningitis, gonorrhea, or a disease caused by infection with HIV, HBV, HCV, HSV, HPV, RSV, CMV, Ebola virus, flavivirus, rotavirus, influenza, coronavirus, EBV, drug-resistant virus, RNA virus, DNA virus, adenovirus, poxvirus, picornavirus, togavirus, orthomyxovirus, retrovirus, hepadnavirus, Gram-negative bacteria, Gram-positive bacteria, atypical bacteria, Staphylococcus, Streptococcus, Escherichia coli, Salmonella, Helicobacter pylori, Chlamydiaceae, Mycoplasmaceae, fungi, protozoa, intestinal worms, worms, prions or parasites. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] FIG1A shows the degradation of estrogen receptor in MCF-7 cells by Western blotting after treatment with exemplary compounds 1, 2, 5, 6, 7 and 13 disclosed herein for 6 hours.
[0057] FIG1B shows the degradation of estrogen receptor in MCF-7 cells by Western blotting after treatment with exemplary compounds 27, 30, 31, 34, 35 and 37 disclosed herein for 6 hours.
[0058] FIG1C shows the degradation of estrogen receptor in MCF-7 cells by Western blotting after treatment with exemplary compounds 44, 46, 47, 48, 57 and 59 disclosed in the present application for 6 hours.
[0059] FIG1D shows the degradation of estrogen receptor in MCF-7 cells after treatment with exemplary compounds 61, 66, 76, 88, 89 and 90 disclosed in the present application for 6 hours, as determined by Western blotting.
[0060] FIG1E shows the degradation of estrogen receptor in MCF-7 cells after treatment with exemplary compounds 103, 104, 110, 119, 120 and 121 disclosed herein for 6 hours, as determined by Western blotting.
[0061] FIG2A shows that MCF-7 cells were treated with 10 nM of exemplary compound 5 disclosed in the present application for different time periods, and the degradation of estrogen receptor in MCF-7 cells was determined by Western blotting.
[0062] FIG2B shows that MCF-7 cells were treated with 10 nM of the exemplary compound 31 disclosed in the present application for different time periods, and the degradation of the estrogen receptor in MCF-7 cells was determined by Western blotting.
[0063] FIG2C shows that MCF-7 cells were treated with 10 nM of exemplary compound 47 disclosed in the present application for different time periods, and the degradation of estrogen receptor in MCF-7 cells was determined by Western blotting.
[0064] FIG2D shows that MCF-7 cells were treated with 10 nM of exemplary compound 48 disclosed in the present application for different time periods, and the degradation of estrogen receptor in MCF-7 cells was determined by Western blotting.
[0065] The six graphs in FIG3A respectively show the inhibitory effects of the exemplary compounds 2, 5, 6, 22, 31 and 34 disclosed in the present application on the proliferation of MCF-7 cells after 6 days of administration.
[0066] The six graphs in FIG3B respectively show the inhibitory effects of exemplary compounds 35, 37, 44, 46, 47 and 48 of the present disclosure on the proliferation of MCF-7 cells after 6 days of administration.
[0067] The five graphs in FIG3C respectively show the inhibitory effects of exemplary compounds 88, 110, 119, 120 and 121 of the present disclosure on the proliferation of MCF-7 cells after 6 days of administration.
[0068] FIG4A shows the degradation of estrogen receptor in T-47D cells after treatment with exemplary compound 34 disclosed in the present application for 4 hours, as determined by Western blotting.
[0069] FIG4B shows the degradation of estrogen receptor in T-47D cells after treatment with exemplary compound 35 disclosed in the present application for 4 hours, as determined by Western blotting.
[0070] FIG5A shows the degradation of estrogen receptor in MCF-7 / ERαY537S cells after treatment with exemplary compound 34 disclosed in the present application for 4 hours. FIG5A shows the degradation of estrogen receptor in MCF-7 / ERαY537S cells by Western blotting.
[0071] FIG5B shows the degradation of estrogen receptor in MCF-7 / ERαY537S cells after treatment with exemplary compound 35 disclosed in the present application for 4 hours. FIG5B shows the degradation of estrogen receptor in MCF-7 / ERαY537S cells by Western blotting.
[0072] FIG5C shows the degradation of estrogen receptor in MCF-7 / ERαY537S cells after treatment with exemplary compound 110 disclosed in the present application for 6 hours. FIG5C shows the degradation of estrogen receptor in MCF-7 / ERαY537S cells by Western blotting.
[0073] FIG5D shows the degradation of estrogen receptor in MCF-7 / ERαY537S cells after treatment with exemplary compound 120 disclosed herein for 6 hours. FIG5D shows the degradation of estrogen receptor in MCF-7 / ERαY537S cells by Western blotting.
[0074] FIG6A shows the degradation of estrogen receptor in MCF-7 / ERαD537G cells after treatment with exemplary compound 110 disclosed herein for 6 hours. FIG6A shows the degradation of estrogen receptor in MCF-7 / ERαD537G cells by Western blotting.
[0075] FIG6B shows the degradation of estrogen receptor in MCF-7 / ERαD537G cells after treatment with exemplary compound 120 disclosed herein for 6 hours. FIG6B shows the degradation of estrogen receptor in MCF-7 / ERαD537G cells by Western blotting.
[0076] FIG7A shows the inhibitory effect of the exemplary compound 110 disclosed in the present application on the proliferation of MCF-7 / ERαY537S cells after 6 days of administration.
[0077] FIG7B shows the inhibitory effect of the exemplary compound 120 disclosed in the present application on the proliferation of MCF-7 / ERαY537S cells 6 days after administration.
[0078] FIG8A shows the dose-dependent growth inhibitory ability of exemplary compound 110 disclosed in the present application in MCF-7 / ERαY537S cell xenograft tumors.
[0079] FIG8B shows that the exemplary compound 110 disclosed in the present application has no effect on the body weight of mice in MCF-7 / ERαY537S cell xenograft tumors.
[0080] FIG9A shows the dose-dependent growth inhibitory ability of exemplary compound 120 disclosed in the present application in MCF-7 / ERαY537S cell xenograft tumors.
[0081] FIG9B shows that the exemplary compound 120 disclosed in the present application has no effect on the body weight of mice in MCF-7 / ERαY537S cell xenograft tumors. DETAILED DESCRIPTION
[0082] definition
[0083] Unless otherwise stated, some of the terms used in the specification and claims of this application are defined as follows:
[0084] As used herein, the term "isomer" includes any and all geometric isomers and stereoisomers. For example, "isomer" includes cis and trans isomers, E and Z isomers, R and S enantiomers, diastereomers, D-isomers, L-isomers, racemic mixtures of the above, and other mixtures thereof. For example, in some embodiments, a stereoisomer can be provided in a form that is substantially free of one or more corresponding enantiomers, which can also be referred to as "stereochemically enriched."
[0085] The term "pharmaceutically acceptable salt" as used herein includes salts that retain the biological effectiveness of the free acid and free base of the specified compound and are not biologically unfavorable. Predictable pharmaceutically acceptable salt forms include, but are not limited to, monosalts, disalts, trisalts, tetrasalts, and the like. Pharmaceutically acceptable salts are non-toxic in the amounts and concentrations in which they are administered. The preparation of these salts can facilitate pharmacological use by altering the physical properties of the compound without hindering the compound from producing its physiological effects. Useful changes in physical properties include lowering the melting point to facilitate transmucosal administration and increasing solubility to facilitate administration of higher concentrations of the drug.
[0086] It is also understood that the compounds of the present application may exist in unsolvated forms, solvated forms (eg, hydrated forms), and solid forms (eg, crystalline or polymorphic forms), and the present application is intended to encompass all such forms.
[0087] As used herein, the terms "solvate," "solvate," or "solvated form" refer to a solvent addition form containing either stoichiometric or non-stoichiometric amounts of a solvent. Some compounds tend to trap fixed molar ratios of solvent molecules in the crystalline solid state, thereby forming a solvate. If the solvent is water, the solvate formed is a hydrate; if the solvent is an alcohol, the solvate formed is an alcoholate. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, methanol, ethanol, DMSO, ethyl acetate, acetic acid, ethanolamine, acetone, diethyl ether, and the like.
[0088] The term "alkyl" as used herein is branched or unbranched, and preferably has 1 to about 12 carbon atoms. A more preferred class of alkyl groups has 1 to about 6 carbon atoms. Even more preferred are alkyl groups having 1, 2, 3 or 4 carbon atoms. Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. Alkyl groups can be substituted or unsubstituted.
[0089] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms, in a group are replaced independently of one another by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and a person skilled in the art can determine (by experiment or theory) which substitutions are possible or impossible without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (e.g., olefinic) bond.
[0090] As used herein, the term "substituted" or "substituted" means, unless otherwise specified, that the group may be substituted by one or more groups selected from the following: alkyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, amino, haloalkyl, and hydroxyalkyl. Whenever a group is described as "optionally substituted with a substituent," the group may be unsubstituted or substituted with one or more of the substituents indicated. Similarly, when a group is described as "unsubstituted or substituted," if it is substituted, the substituent may be selected from one or more of the substituents indicated. If no substituents are specified, it means that the group shown as "optionally substituted with substituents" or "substituted" may be substituted by one or more groups selected individually or independently from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, heteroaralkyl, (heteroalicyclic)alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, thiol, alkylthio, arylthio, cyano, halogen, thiocarbonyl, O-carbamoyl, N- -carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amide, N-amide, S-sulfonamide, N-sulfonamide, C-carboxyl, protected C-carboxyl, O-carboxyl, isocyanate, thiocyanate, isothiocyanate, nitro, silyl, sulfo, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, amino, monosubstituted amino and disubstituted amino groups and protected derivatives thereof.
[0091] The term "halogen" as used herein refers to F, Cl, Br or I.
[0092] As used herein, the term "cyano" refers to -CN.
[0093] As used herein, the term "hydroxy" refers to -OH.
[0094] The term "amine" as used herein refers to -NH2.
[0095] As used herein, the term "oxy" refers to an oxygen atom double-bonded to another atom (eg, carbon or sulfur). For example, if directly attached to a carbon atom, a carbonyl group (C=O) is formed.
[0096] As used herein, the term "acyl" refers to a carbonyl-containing functional group, such as -C(=O)R', where R' is hydrogen or a hydrocarbon group. In some embodiments, the acyl group is a group represented by the formula alkylC(O)-.
[0097] The term "alkoxy" as used herein, whether used as part of another term or by itself, refers to an alkyl group, as defined above, attached to the parent molecular group through an oxygen atom.
[0098] As used herein, the term "benzyl" refers to a -CH2-phenyl group.
[0099] As used herein, the term "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.
[0100] The term "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions and / or dosage forms that are suitable for use in contact with human or animal tissues without excessive toxicity, irritation, allergic reactions, other problems or complications, and with a reasonable benefit / risk ratio. In some embodiments, pharmaceutically acceptable compounds, materials, compositions and / or dosage forms refer to those approved by regulatory agencies (such as the U.S. Food and Drug Administration, the China National Medical Products Administration, the European Medicines Agency) or listed in recognized pharmacopoeias (such as the U.S. Pharmacopoeia, the Chinese Pharmacopoeia, the European Pharmacopoeia) for use in animals, particularly humans, materials, compositions and / or dosage forms.
[0101] The term "pharmaceutically acceptable carrier" as used herein refers to a pharmaceutically acceptable material, composition or vehicle for carrying or transporting the compound of the present application or a pharmaceutically acceptable salt thereof from one position, body fluid, tissue, organ (inside or outside) or body part to another position, body fluid, tissue, organ or body part, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. A pharmaceutically acceptable carrier can be a vehicle, diluent, excipient or other material that can be used to contact animal tissue without excessive toxicity or adverse reactions. Exemplary pharmaceutically acceptable carriers include, but are not limited to, sugars, starches, cellulose, malt, tragacanth gum, gelatin, Ringer's solution, alginic acid, isotonic saline, buffers, etc. Pharmaceutically acceptable carriers that can be used for the present application include those known in the art, such as those disclosed in "Remington Pharmaceutical Sciences" Mack Pub. Co., New Jersey (1991).
[0102] The term "subject" as used herein refers to an organism, tissue, or cell. The subject may include a human subject for medical purposes (e.g., diagnosis and / or treatment of an existing condition or disease, or prophylactic treatment to prevent the onset of a condition or disease), or an animal subject for medical veterinary purposes or development purposes. The subject also includes sample materials from tissue culture, cell culture, organ replication, stem cell production, etc. Suitable animal subjects include mammals and birds. The term "mammal" as used herein includes, but is not limited to, primates (e.g., humans, monkeys, apes, etc.), cattle (e.g., bulls, etc.), sheep (e.g., sheep, goats, etc.), pigs, horses, cats, dogs, rabbits, rodents (e.g., mice, rats, etc.), etc. The term "bird" as used herein includes, but is not limited to, chickens, ducks, geese, quail, turkeys, pheasants, etc. In some embodiments, the subject is a mammal or a mammalian cell. In some embodiments, the subject is a human or a human cell. Human subjects include, but are not limited to, fetuses, newborns, infants, adolescents, and adult subjects. In addition, a "subject" may include a patient suffering from or suspected of having a certain condition or disease. Therefore, the terms "subject" and "patient" are used interchangeably herein. A subject can also refer to cells in the laboratory or bioprocess culture medium during testing.
[0103] As used herein, the term "effective amount" refers to an amount of a drug or pharmaceutical agent that will elicit a biological or medical response in a tissue, system, animal, or human that is sought by, for example, a researcher or clinician. In addition, the term "therapeutically effective amount" means any amount that results in improved treatment, cure, prevention, or alleviation of a disease, disorder, or side effect, or a decrease in the rate of progression of a disease or disorder, compared to a corresponding control subject that has not received such an amount. The term also includes within its scope an amount that effectively enhances normal physiological function. The therapeutically effective amount of one or more compounds of the present application is known to those skilled in the art or can be readily determined by standard methods known in the art.
[0104] Additionally, it should be noted that, unless explicitly stated otherwise, the phrase "...independently selected" used in this application should be broadly interpreted, meaning that each substituent described is independently selected from the others. Therefore, each substituent may be the same as or different from the others. More specifically, the phrase "...independently selected" can mean that the specific options represented by the same symbol in different groups do not affect each other, or that the specific options represented by the same symbol in the same group do not affect each other.
[0105] Those skilled in the art will understand that, according to the conventions used in the art, the structural formulas used in this application to describe groups are and The examples refer to the corresponding groups shown being connected to other fragments and groups in the compound through the SP3-SP3 covalent bond at that site. Without violating the common sense in the art, the above preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present application.
[0106] Compounds of the present application
[0107] The present application provides a PROTAC compound targeting an estrogen receptor as shown in formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof:
[0108] Among them, L represents a connecting chain, which is used to connect the ERL fragment and E3L; E3L represents the ubiquitin ligase ligand, which can recruit E3 ligase to form a stable target protein-PROTAC-E3 ubiquitin ligase ternary complex. After the target protein is tagged with ubiquitination, the ubiquitinated protein is recognized and degraded by the proteasome 26S in the cell.
[0109] in, Indicates absence, substitution or unsubstituted Substituted or unsubstituted X 4 represents N or CRa, and the substituent is selected from halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amine, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl;
[0110] When A does not exist, R 1 Selected from halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl;
[0111] X 1 N or CR 3 ;
[0112] X 2 or X 3 Each independently selected from CH, CR 3 and N;
[0113] R 2 、R 3 Each is independently selected from H, halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl;
[0114] Ra is selected from H, halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl;
[0115] L is selected from the following:
[0116] Those skilled in the art will appreciate that the E3L of the present application may be any ubiquitin ligase ligand known in the art.
[0117] In a specific embodiment, E3L is selected from one of the following:
[0118] In a specific embodiment, E3L is
[0119] In a specific embodiment, L is selected from the following:
[0120] In a specific embodiment, L is
[0121] In a specific embodiment, when A is absent, R 1 Selected from -NH2 or -OH.
[0122] In a specific embodiment, X 4 is N.
[0123] In a specific embodiment, X 4 is CRa, Ra is selected from H, halogen and hydroxyl. In a specific embodiment, X 4 is CRa, Ra is H.
[0124] In a specific embodiment, X 1 CR 3 , R 3 is H, CH3O or F. In a specific embodiment, X 1 CR 3 , R 3 For H.
[0125] In a specific embodiment, X 2 In one embodiment, X 2 is N.
[0126] In a specific embodiment, X3 For CH.
[0127] In a specific embodiment, R 2 For H.
[0128] In a specific embodiment, the compound is as shown in formula (I):
[0129] in, Indicates halogen substituted or unsubstituted X 4 CH; X 1 CR 3 , R 3 is H, CH3O or F; X 2 is CH or N; X 3 CH; R 2 Selected from H, halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl;
[0130] L is selected from the following:
[0131] E3L is selected from one of the following:
[0132] In a specific embodiment, the compound is as shown in formula (I):
[0133] in, Indicates halogen substituted or unsubstituted X 4 CH; X 1 CR 3 , R 3 is H, CH3O or F; X 2 is CH or N; X 3 CH; R 2 Selected from H, halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl;
[0134] L is
[0135] E3L is selected from one of the following:
[0136] In a specific embodiment, the compound represented by formula (I) is represented by formula (II):
[0137] Among them, R 4 Selected from halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl.
[0138] In a specific embodiment, R 4 In one embodiment, R 4 For F.
[0139] In a specific embodiment, the compound is as shown in formula (II):
[0140] Among them, R 4 is a halogen; X 1 CR 3 , R 3 is H, CH3O or F; X 2 is CH or N; X 3 CH; R 2 Selected from H, halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl;
[0141] L is selected from the following:
[0142] E3L is selected from one of the following:
[0143] In a specific embodiment, the compound is as shown in formula (II):
[0144] Among them, R 4 is a halogen; X 1 CR 3 , R 3 is H, CH3O or F; X 2 is CH or N; X 3 CH; R 2 Selected from H, halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amino, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl;
[0145] L is
[0146] E3L is selected from one of the following:
[0147] In a specific embodiment, the compound represented by formula (I) is represented by formula (III):
[0148] In a specific embodiment, the compound is as shown in formula (III):
[0149] L is selected from the following:
[0150] E3L is selected from one of the following:
[0151] In a specific embodiment, the compound is as shown in formula (III):
[0152] L is
[0153] E3L is selected from one of the following:
[0154] In a specific embodiment, the compound represented by formula (I) is represented by formula (IV):
[0155] In a specific embodiment, the compound is as shown in formula (IV):
[0156] L is selected from the following:
[0157] In a specific embodiment, the compound is as shown in formula (IV):
[0158] L is
[0159] In a specific embodiment, the compound involved in the present application is any one of Compound 1-Compound 143.
[0160] Pharmaceutical composition
[0161] The present application also provides a pharmaceutical composition comprising any one of the above compounds, pharmaceutically acceptable salts, solvates, hydrates, or isomers, and a pharmaceutically acceptable carrier.
[0162] The form of the pharmaceutical composition depends on a number of criteria, including, for example, the route of administration, the extent of the disease, or the dose to be administered.
[0163] In some embodiments, the pharmaceutical composition can be formulated for delivery to a subject by an appropriate route, including but not limited to, oral route, injection route (e.g., intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, intracardiac injection, intrathecal injection, intrapleural injection, intraperitoneal injection, etc.), mucosal route (e.g., intranasal administration, oral administration, etc.), sublingual route, rectal route, transdermal route, intraocular route, pulmonary route. Depending on the desired route of administration, the pharmaceutical composition can be formulated as tablets, capsules, pills, dragees, powders, granules, cachets, lozenges, suppositories, suspensions, emulsions, syrups, aerosols (as solid or in liquid media), sprays, ointments, pastes, patches, creams, lotions, gels, inhalants, etc.
[0164] Therapeutic uses and treatments
[0165] The present application also provides the use of any one of the above compounds or pharmaceutically acceptable salts, solvates, hydrates, isomers or pharmaceutical compositions thereof in treating diseases that are treated by degrading a target protein bound to a targeting ligand.
[0166] The present application also provides the use of any one of the above compounds or pharmaceutically acceptable salts, solvates, hydrates, isomers or pharmaceutical compositions thereof in the preparation of drugs for treating diseases that are treated by degrading target proteins bound to targeting ligands.
[0167] The present application also provides a method for treating a disease in a subject by degrading a target protein bound to a targeting ligand, comprising administering to the subject an effective amount of any one of the above-mentioned compounds or a pharmaceutically acceptable salt, solvate, hydrate, or isomer or pharmaceutical composition thereof.
[0168] Wherein, the disease is selected from abnormal cell proliferation, cancer, immune disease, diabetes, cardiovascular disease, infectious disease and inflammatory disease.
[0169] In a specific embodiment, the cancer is selected from breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, endometriosis, fallopian tube tumors, ovarian tumors, leukemia, skin cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, bladder cancer, intestinal cancer, colon cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer, neck cancer, pancreatic cancer, stomach cancer, lymphoma, non-Hodgkin's lymphoma, melanoma, myeloproliferative disease, sarcoma, angiosarcoma, Peripheral neuroepithelial tumor, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, neuroblastoma, gangliocytoma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningiosarcoma, neurofibroma, schwannoma, thyroid cancer, Hodgkin's tumor, Wilms' tumor and teratoma; more preferably selected from breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, fallopian tube tumor and ovarian tumor.
[0170] In a specific embodiment, the cancer is selected from breast cancer, endometrial cancer, ovarian cancer, cervical cancer, prostate cancer, or endometriosis.
[0171] In a specific embodiment, the infectious disease is selected from viral pneumonia, avian influenza, meningitis, gonorrhea, or infection with HIV, HBV, HCV, HSV, HPV, RSV, CMV, Ebola virus, flavivirus, trachea virus, rotavirus, influenza, coronavirus, EBV, drug-resistant virus, RNA virus, DNA virus, adenovirus, poxvirus, picornavirus, togavirus, orthomyxovirus, retrovirus, hepadnavirus, Gram-negative bacteria, Gram-positive bacteria, atypical bacteria, Staphylococcus, Streptococcus, Escherichia coli, Salmonella, Helicobacter pylori, Chlamydiaceae, Mycoplasmaceae, fungi, protozoa, intestinal worms, worms, prions or parasites.
[0172] Example
[0173] The present application is further illustrated by way of examples. Synthesis examples and biological examples described herein are provided to illustrate the compounds, pharmaceutical compositions, and methods provided herein. The following examples are intended to illustrate the present application only and are not intended to limit the present application. Any modifications, variations, and modifications made within the scope of the present application are within the scope of the present application.
[0174] The compounds provided herein can be prepared from readily available starting materials using the specific synthetic schemes described below and the procedures well known to those skilled in the art. The experimental methods in the following examples where specific conditions are not specified are determined by conventional methods and conditions by those skilled in the art through routine optimization procedures.
[0175] The abbreviations in the examples are shown in the table below:
[0176] Unless otherwise stated, the compounds herein include different stereoisomers having the same molecular formula. "Stereoisomers" herein also include enantiomers and diastereomers. Enantiomers are optical isomers, and diastereomers are stereoisomers with achiral enantiomers. Different isomers having the same molecular formula as the compounds of the present application are also within the scope of protection of the present application.
[0177] Unless otherwise specified, the term "solvate" herein may also be referred to as "solvate compound". "Solvate" refers to a compound containing a solvent, wherein the solvent molecules may be combined with the compound molecules in other ways including coordination bonds, covalent bonds, van der Waals forces, ionic bonds, hydrogen bonds, etc.
[0178] Unless otherwise indicated, the term "pharmaceutically acceptable salt" herein refers to the compound of the present application and / or the salt formed, which is chemically or physically compatible with the other ingredients constituting a certain pharmaceutical dosage form and physiologically compatible with the receptor. "Pharmaceutically acceptable salt" can be acidic and / or basic salts formed with inorganic and / or organic acids and bases, and also includes zwitterionic salts (inner salts), and also includes quaternary ammonium salts, such as alkylammonium salts. These salts can be obtained directly in the final separation and purification of the compound. It can also be obtained by appropriately mixing the compound of the present application or its stereoisomer or solvate with a certain amount of acid or base. These salts may form a precipitate in the solution and be collected by filtration, or recovered after solvent evaporation, or obtained by cooling and drying after reaction in an aqueous medium.
[0179] Unless otherwise stated, this application uses traditional methods such as mass spectrometry and nuclear magnetic resonance to identify compounds, and each step and condition can refer to the conventional operating steps and conditions in the art.
[0180] Unless otherwise indicated, this application employs standard nomenclature and standard laboratory procedures and techniques in analytical chemistry, synthetic organic chemistry, and optics. In some cases, standard techniques are used for chemical syntheses, chemical analyses, and light-emitting device performance testing.
[0181] Unless otherwise stated, Minute TM The total protein extraction kit was purchased from Chenxue Biotechnology (Guangzhou) Co., Ltd., product number SD-001 / SN-002.
[0182] Unless otherwise stated, the Bio-Rad Trans-Blot Turbo in this application was purchased from Shanghai Aiyan Biotechnology Co., Ltd.
[0183] Unless otherwise stated, 5× SDS-PAGE loading buffer was purchased from Shanghai Lianmai Bioengineering Co., Ltd., product number: LM-071.
[0184] Unless otherwise specified, “5-bromo-1-H-indazole” herein was purchased from Shanghai Yuanye Biotechnology Co., Ltd., product number: Y11003.
[0185] Unless otherwise specified, the Dress-Martin reagent herein is also referred to as Dress-Martin oxidant and is purchased from Hede Chemical (Suzhou) Co., Ltd.
[0186] Unless otherwise stated, 4-bromo-2,6-difluorobenzaldehyde was purchased from MacLean Reagent Co., Ltd., CAS No. 537013-51-7.
[0187] Unless otherwise specified, 4-fluorobenzaldehyde in this article was purchased from Gaide Chemical Technology (Shanghai) Co., Ltd., CAS No.: 459-57-4.
[0188] Unless otherwise specified, 5-fluoropyridine-2-carboxaldehyde herein was purchased from Gaide Chemical Technology (Shanghai) Co., Ltd., CAS No.: 31181-88-1.
[0189] Unless otherwise specified, 5-fluoroisobenzofuran-1,3-dione in this article was purchased from Gaide Chemical Technology (Shanghai) Co., Ltd., CAS No.: 319-03-9.
[0190] Unless otherwise specified, “dihydrouracil” herein was purchased from Shanghai Aladdin Technology Co., Ltd., CAS No. 504-07-4.
[0191] Unless otherwise specified, 7-bromo-imidazole[1,2-a]pyridine was purchased from Shanghai Tebo Chemical Technology Co., Ltd. with a CAS number of 808744-34-5.
[0192] Unless otherwise specified, “N-iodosuccinimide” herein was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., CAS No. 516-12-1.
[0193] Unless otherwise specified, "(1R, 2R)-N1, N2-dimethylcyclohexane-1, 2-diamine" herein was purchased from Shanghai Jixiang Biotechnology Co., Ltd., product number: SH215137.
[0194] Unless otherwise specified, “5,6-dimethylisoindolin-1-one” herein was purchased from Shanghai Yuanye Biotechnology Co., Ltd., CAS No.: 110568-65-5.
[0195] Unless otherwise specified, dibenzoyl peroxide herein was purchased from Jinan Huifengda Chemical Co., Ltd., CAS No. 94-36-0.
[0196] Unless otherwise specified, “5,6-dimethylisobenzofuran-1,3-dione” in this article was purchased from Shanghai Haohong Biopharmaceutical Technology Co., Ltd., CAS No. 129-64-6.
[0197] Unless otherwise specified, “3-amino-1-(4-methoxybenzyl)piperidine-2,6-dione” herein was purchased from Chongqing Kalan Pharmaceutical Co., Ltd., CAS No. 1834336-02-5.
[0198] Unless otherwise indicated, "tert-butyl 3-formylazetidine-1-carboxylate" herein was purchased from Shanghai Carlo Chemical Co., Ltd., CAS No. 177947-96-5.
[0199] Unless otherwise specified, "di-tert-butyl[2',4',6'-tri(propan-2-yl)-[1,1'-biphenyl][1,1'-biphenyl]-2-yl]phosphane" herein was purchased from Shaoyuan Technology, CAS No.: 1160861-53-9.
[0200] Unless otherwise specified, 2-methylpropane-2-amine was purchased from Shanghai MacLean Biochemical Technology Co., Ltd., CAS No. 75-64-9.
[0201] Unless otherwise specified, “chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)(2-amino-1,1′-biphenyl-2-yl)palladium(II)” herein was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., CAS No.: 1375325-68-0.
[0202] Unless otherwise stated, the TBST buffer used in this article was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0203] Intermediate Synthesis Example
[0204] The present invention is further illustrated by way of examples. Synthetic and biological examples described herein are provided to illustrate the compounds, pharmaceutical compositions, and methods provided herein. The following examples are intended to illustrate the present invention only and are not intended to limit the present invention. Modifications, changes, and variations made within the scope of the present invention are within the scope of the present invention.
[0205] Preparation of Estrogen Receptor Protein Binding Ligand Small Molecule Fragment ERL:
[0206] Preparation of ERL-1: 3-fluoro-5-((6-fluoropyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-tetrahydro-2H-pyran-4-yl)-1H-indazole:
[0207] Step 1: Preparation of 5-bromo-3-fluoro-1H-indazole:
[0208] To a solution of 5-bromo-1H-indazole (200 g, 1.01 mol) in DMA (2 L) stirred on an ice bath, Selectfluor (719 g, 2.03 mol) was added dropwise under a nitrogen atmosphere. The resulting mixture was stirred at 60°C for 12 hours. After warming to room temperature, water (200 mL) was added to quench the reaction. The resulting mixture was extracted with ethyl acetate (3×1500 mL), and the combined organic layers were washed with water (3×500 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and then eluted with CH2Cl2 / PE (1:1) to give 5-bromo-3-fluoro-1H-indazole (82 g, 37.57%) as a white solid. LCMS (ES, m / z): 215 [M+H] + .
[0209] Step 2: Preparation of 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-3-fluoro-indazole:
[0210] Under a nitrogen atmosphere, dihydro-2H-pyran (32 g, 380.7 mmol) and pTsOH (8.7 g, 50.8 mmol) were added to a stirred solution of 5-bromo-1H-indazole (50 g, 253.8 mmol) in ice-cold DCM (800 mL). The resulting mixture was stirred for 4 hours after warming to room temperature. The reaction was quenched by adding a saturated aqueous solution of sodium bicarbonate, and the resulting mixture was extracted with DCM (3 x 1000 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (5:1) to give 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-3-fluoro-indazole (60 g, 81%) as a yellow oily liquid. LCMS (ES, m / z): 299 [M+H] + .
[0211] Step 3: Preparation of (4-(6-fluoropyridin-3-yl))(1-(tetrahydro-2H-pyran-2-yl)-1H-3-fluoro-indazol-5-yl)methanol:
[0212] A solution of 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (10 g, 35.6 mmol) in THF (200 mL) was treated with n-butyl lithium in n-hexane (2.5 M, 17 mL, 42.7 mmol) at -78 ° C under a nitrogen atmosphere for 5 minutes, followed by the addition of 6-fluoropyridine-3-carboxaldehyde (6.7 g, 53.4 mmol). The resulting mixture was stirred at -78 ° C for 1 hour. The reaction was quenched with saturated aqueous ammonium chloride solution and allowed to rise to room temperature. The resulting mixture was extracted with ethyl acetate (3x50 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA to give (4-(6-fluoropyridin-3-yl))(1-(tetrahydro-2H-pyran-2-yl)-1H-3-fluoro-indazol-5-yl)methanol (7 g, 58%) as a white solid. LCMS (ES, m / z): 346 [M+H] + .
[0213] Step 4: Preparation of (3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(6-fluoropyridin-3-yl)methanone:
[0214] To a solution of (4-(6-fluoropyridin-3-yl))(1-(tetrahydro-2H-pyran-2-yl)-1H-3-fluoro-indazol-5-yl)methanol (7 g, 21.4 mmol) in ice-cold DCM (150 mL) was added Dess-Martin reagent (13.6 g, 32.1 mmol). The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with DCM. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and then eluted with PE / EA (10:1) to give (3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(6-fluoropyridin-3-yl)methanone (4 g, 55%) as an off-white solid. LCMS (ES, m / z): 344 [M+H] + .
[0215] Step 5: Preparation of 3-fluoro-5-((6-fluoropyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-tetrahydro-2H-pyran-4-yl)-1H-indazole:
[0216] Zinc powder (4 g, 61.5 mmol) and TiCl4 (4.7 g, 24.6 mmol) were added to a stirred ice bath THF (200 mL) under a nitrogen atmosphere. The resulting mixture was stirred at 65 ° C for 2 hours, cooled to 0 ° C and added 2,2,6,6-tetramethyltetrahydro-4H-pyran-4-one (1.5 g, 9.2 mmol) and (3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole-5-yl) (6-fluoropyridin-3-yl)methanone (2 g, 6.2 mmol). The resulting mixture was stirred at 65 ° C for 12 hours. The reaction was quenched with saturated sodium bicarbonate aqueous solution after cooling to room temperature. The resulting mixture was extracted with ethyl acetate (3x200 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EA (5:1) to give 3-fluoro-5-((6-fluoropyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-tetrahydro-2H-pyran-4-yl)-1H-indazole (1.5 g, 52%) as an off-white solid. LCMS (ES, m / z): 468 [M+H] + .
[0217] Unless otherwise indicated, the intermediates and analogs described below (not limited to analogs having different substitutions, such as halogens) were prepared according to analogous procedures described above for the ERL-1 embodiment using corresponding analogous starting materials and reagents.
[0218] ERL-2: 5-((6-fluoropyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole, LCMS: [M+H] + =450.2.
[0219] The synthesis method is similar to that of ERL-1, omitting the fluorination step in step 1.
[0220] ERL-3: 5-((4-chlorophenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole, LCMS: [M+H] + =483.2.
[0221] The synthesis method is similar to that of ERL-1, except that 4-fluorobenzaldehyde is used in place of 6-fluoropyridine-3-carboxaldehyde in step 3.
[0222] ERL-4: 5-((4-chlorophenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole, LCMS: [M+H] + =465.2.
[0223] The synthesis method is similar to that of ERL-1, except that step 1 is omitted and 4-fluorobenzaldehyde is used instead of 6-fluoropyridine-3-carboxaldehyde in step 3.
[0224] ERL-5: 5-((4-bromo-2,6-difluorophenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-methylene)methyl)-3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole, LCMS: [M+H] + =563.1.
[0225] See ERL-1 for the synthesis method.
[0226] ERL-6: 3-Fluoro-5-((5-fluoropyridin-2-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole
[0227] The synthesis method is similar to that of ERL-1, except that 5-fluoropyridine-2-carboxaldehyde is used instead of 6-fluoropyridine-3-carboxaldehyde in step 3.
[0228] Preparation of small molecule fragment E3L that binds to E3 ubiquitin ligase:
[0229] Preparation of E3L-1:2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione:
[0230] To a solution of 5-fluoroisobenzofuran-1,3-dione (15g, 90mmol) in acetic acid (150mL), sodium acetate (14.8g, 180mmol) and 3-aminopiperidine-2,6-dione hydrochloride (14.6g, 90mmol) were added. The mixture was stirred at 120°C for 12 hours. The reaction mixture was concentrated under reduced pressure to remove most of the acetic acid. The residue was poured into water (200mL) and stirred for 15 minutes. The mixture was filtered. The filter cake was washed with water (50mLX 2) and dried to obtain 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (21g, 90% yield) as an off-white solid. LC-MS (ESI) m / z:277.1[M+1] + ;
[0231] Preparation of E3L-2 piperazine hydrochloride: 3-(1-oxo-5-(piperazin-1-yl)isoindol-2-yl)piperidine-2,6-dione hydrochloride:
[0232] Step 1: Preparation of tert-butyl 4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-isoindol-5-yl]piperazine-1-carboxylic acid:
[0233] Under a nitrogen atmosphere, tert-butylpiperazine-1-carboxylate (13.8 g, 74.3 mmol), Cs2CO3 (24.2 g, 74.3 mmol) and 2,3-bis[2,6-bis(pentan-3-yl)phenyl]-2,3-dihydro-1H-imidazol-2-yl]dichloro(3-chloropyridin-1-ammonium-1-yl)palladium (2.0 g, 2.5 mmol) were added to a solution of 3-(5-bromo-1-oxoisoindol-2-yl)piperidine-2,6-dione (8 g, 24.8 mmol) in 1,4-dioxane (100 mL) in sequence. The resulting mixture was heated to 100 ° C and stirred for 4 h. The reaction was cooled to room temperature and quenched with water. The precipitated solid was collected by filtration and washed with H2O (2×15 mL). The residue was washed and slurried with ethyl acetate (2×10 mL). The resulting solid was dried under infrared light. Tert-butyl 4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]piperazine-1-carboxylic acid (5 g, 47.13%) was obtained as an off-white solid. LCMS (ES, m / z): 429 [M+H] + .
[0234] Step 2: Preparation of 3-[1-oxo-5-(piperazin-1-yl)isoindol-2-yl]piperidine-2,6-dione hydrochloride:
[0235] Tert-butyl 4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-isoindol-5-yl]piperazine-1-carboxylic acid (5 g, 11.7 mmol) and hydrochloric acid (4 M, 10 mL) were stirred in ethyl acetate (30 mL) overnight. The resulting mixture was concentrated under reduced pressure. The residue was washed with ethyl acetate (5 x 20 mL) and slurried. 3-(1-oxo-5-(piperazin-1-yl)-3H-isoindol-2-yl]piperidine-2,6-dione hydrochloride (3 g, 70.47%) was obtained as an off-white solid. LCMS (ES, m / z): 329 [M+H] + .
[0236] Preparation of E3L-3:1-(7-bromoimidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione:
[0237] Step 1: Preparation of 3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione:
[0238] Dissolve the raw material dihydrouracil (6.0g, 52.6mmol) in DMF (100mL), add Cs2CO3 (34.5g, 106mmol) at 25 degrees, and then slowly add PMBCl (7.5g, 47.5mmol) at room temperature. React at room temperature for 2h. After the reaction is complete, filter and wash the filter cake with EA (50mL×2). Combine the filtrates and pour into water (300mL), then extract with EA (200mL×2). Combine the organic phases, wash once with water (200mL), and then wash once with saturated brine (200ml). The organic phase is dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product is dissolved in EA / PE (1 / 150mL) and stirred for 30 minutes, filtered, and dried. 5.9g of white solid is obtained, with a yield of 47%. LCMS: [M+H] + =235.2.
[0239] Step 2: Preparation of 7-bromo-3-iodoimidazole[1,2-a]pyridine:
[0240] Dissolve the raw material 7-bromo-imidazole[1,2-a]pyridine (11.4 g, 54.9 mmol) in DMF (160 mL) and add NIS (15.6 g, 69.4 mmol) at 25°C. Reaction was allowed to proceed at 100°C for 1 h. After completion of the reaction, the mixture was poured into water (500 mL) and extracted with EA (200 mL x 2). The combined organic phases were washed once with water (200 mL) and once with saturated brine (200 mL). The organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated by column chromatography using EA / PE (0-5%) to afford 7-bromo-3-iodoimidazole[1,2-a]pyridine as a dark brown solid (14.1 g, 75% yield). LCMS: [M+H]+ = 322.9.
[0241] Step 3: Preparation of 1-(7-bromoimidazo[1,2-a]pyridin-3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione:
[0242] Dissolve the raw materials 3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (6 g, 25.1 mmol) and 7-bromo-3-iodoimidazole[1,2-a]pyridine in 1,4-dioxane (150 mL). Add Cs2CO3 (16.7 g, 51.2 mmol), CuI (980 mg, 5.22 mmol), and (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (730 mg, 5.23 mmol) at 25°C. Reaction was allowed to proceed at 80°C under nitrogen for 16 h. After completion of the reaction, the mixture was poured into water (300 mL) and extracted with EA (150 mL x 2). The combined organic phases were washed once with water (200 mL) and then once with saturated brine (200 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated by column chromatography using EA / PE (1 / 10 to 1 / 0) to afford 1-(7-bromoimidazo[1,2-a]pyridin-3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (3.1 g, 29% yield) as a yellow solid. LCMS: [M+H]+ = 429.0.
[0243] Step 4: Preparation of 1-(7-bromoimidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione:
[0244] The starting material, 1-(7-bromoimidazo[1,2-a]pyridin-3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (3.1 g, 7.48 mmol), was dissolved in TfOH (2.3 mL) and reacted at 65°C for 4 h. After completion of the reaction, the solution was concentrated and the pH was adjusted to between 6 and 7 with TEA at 0°C. The solution was further concentrated and then EA (30 mL) was added and stirred for half an hour. Filtration and drying afforded 1-(7-bromoimidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione as a white solid (2.12 g, 76% yield). LCMS: [M+H] + =309.0.
[0245] Preparation of E3L-4:1-(8-bromoimidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione:
[0246] Step 1: Preparation of 8-bromo-3-iodoimidazole[1,2-a]pyridine:
[0247] Dissolve the raw material 8-bromo-imidazole[1,2-a]pyridine (10 g, 50.1 mmol) in DMF (150 mL) and add NIS (13.6 g, 60.2 mmol) at 25°C. Reaction was allowed to proceed at 100°C for 1 h. After completion of the reaction, the mixture was poured into water (400 mL) and extracted with EA (200 mL x 2). The combined organic phases were washed once with water (200 mL) and once with saturated brine (200 mL). The organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated by column chromatography using EA / PE (5%) to obtain 8-bromo-3-iodoimidazole[1,2-a]pyridine as a dark brown solid (12.2 g, 77% yield).
[0248] LCMS: [M+H]+=322.9.
[0249] Step 2: Preparation of 1-(8-bromoimidazo[1,2-a]pyridin-3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione:
[0250] Dissolve the raw materials 3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (4.4 g, 18.65 mmol) and 8-bromo-3-iodoimidazole[1,2-a]pyridine in 1,4-dioxane (100 mL). Add Cs2CO3 (11.1 g, 34.1 mmol), CuI (705 mg, 3.71 mmol), and (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (522 mg, 3.72 mmol) at 25°C. React at 80°C under nitrogen for 16 hours. After completion of the reaction, pour into water (200 mL) and extract with EA (100 mL x 2). Combine the organic phases, wash once with water (200 mL), and then once with saturated brine (200 mL). Dry over anhydrous sodium sulfate, filter, and concentrate. The crude product was separated by column chromatography using EA / PE (1 / 10 to 1 / 0) to give a yellow solid 1-(8-bromoimidazo[1,2-a]pyridin-3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (2.3 g, 29% yield). LCMS: [M+H] + =429.0.
[0251] Step 3: Preparation of 1-(8-bromoimidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione
[0252] The starting material, 1-(8-bromoimidazo[1,2-a]pyridin-3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (2.3 g, 5.36 mmol), was dissolved in TfOH (1.5 mL) and reacted at 65°C for 4 h. After completion of the reaction, the mixture was concentrated and the pH was adjusted to between 6 and 7 with TEA at 0°C. The mixture was further concentrated and then EA (30 mL) was added and stirred for half an hour. Filtration and drying afforded 1-(8-bromoimidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione as a white solid (1.55 g, 81% yield). LCMS: [M+H]+ = 309.0.
[0253] Preparation of E3L-5: 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione:
[0254] Step 1: Preparation of 2-bromo-N-methyl-6-nitroaniline:
[0255] Dissolve the raw material 1-bromo-2-fluoro-3-nitrobenzene (20 g, 91 mmol) in THF (20 mL), then add methylamine (2 M, 200 mL). Reaction was allowed to proceed at 60°C for 12 h. After completion of the reaction, the reaction mixture was poured into NaHCO₃ (20 mL) and extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (2 x 100 mL). The organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. 20 g of 2-bromo-N-methyl-6-nitroaniline was obtained as a red oil in a 94% yield. LCMS (ESI), m / z: [M+H] + =230.9.
[0256] Step 2: Preparation of 6-bromo-N1-toluene-1,2-diamine:
[0257] Dissolve the raw material 2-bromo-N-methyl-6-nitroaniline (11g, 48mmol) in EA (150mL), water (5mL), and AcOH (50mL). Heat to 50°C. Add iron powder (12.2g, 201mmol) at 50°C, and heat to 80°C for 4 hours. After the reaction is complete, filter and add concentrated acid to the filtrate. Add 100mL of water and extract with EA (100mL x 3). Combine the organic phases, wash once with water (200mL), and once with saturated brine (200mL). Dry over anhydrous sodium sulfate, filter, and concentrate. Obtain 10g of 6-bromo-N1-methylbenzene-1,2-diamine as a crude red oil (98% yield). LCMS: [M+H]+ = 201.1.
[0258] Step 3: Preparation of 7-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one:
[0259] Dissolve the raw material 6-bromo-N1-methylbenzene-1,2-diamine (10 g, 98 mmol) in MeCN (150 mL), then add CDI (16 g, 98 mmol). Reaction was allowed to proceed at 85°C under nitrogen for 12 hours. After completion of the reaction, the solvent was removed by rotary evaporation and the mixture was poured into water (100 mL). A solid precipitated, which was then filtered. The filter cake was washed with water and dried to yield 10.5 g of 7-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one as a white solid, an 89% yield. LCMS: [M+H]+ = 227.0.
[0260] Step 4: Preparation of 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(4-methoxybenzyl)piperidine-2,6-dione:
[0261] Dissolve the raw material 7-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (12g, 27mmol) in THF (300mL), then add t-BuOK (3.6g, 32mmol) and react at 0°C for 0.5h. Then, dissolve 1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl trifluoromethanesulfonate (10.1g, 27mmol) in THF (50mL) and slowly add the reaction solution. Continue the reaction at 20°C for half an hour. After completion, quench the reaction with saturated ammonium chloride (50mL) and extract with EA (100mL). The combined organic phases are washed with saturated brine, dried, filtered, and concentrated. The crude product was purified by reverse HPLC (0.1% TFA) to give 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(4-methoxybenzyl)piperidine-2,6-dione as a yellow solid (6.8 g, 56% yield).
[0262] Step 5: Preparation of 4-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione:
[0263] Dissolve the starting material, 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(4-methoxybenzyl)piperidine-2,6-dione (6.8 g, 13.6 mmol), in TfOH (4.8 mL) and react at 65°C for 4 h. After the reaction, concentrate the mixture and adjust the pH to between 6 and 7 with TEA at 0°C. Continue concentrating the mixture and then add EA (100 mL) and stir for half an hour. Filter and dry to obtain 4-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione as a white solid (4.55 g, 81% yield). LCMS: [M+H] + =309.0.
[0264] Preparation of E3L-6:3-(1-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione:
[0265] Preparation of 1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl trifluoromethanesulfonate:
[0266] To a solution of 3-hydroxy-1-(4-methoxybenzyl)piperidine-2,6-dione (43.0 g, 173 mmol) in DCM (500 mL), pyridine (27.3 g, 345 mmol) was first added, followed by trifluoromethanesulfonic anhydride (73.0 g, 258.74 mmol) at 0°C. Stirring was continued at 0°C for 2 hours under nitrogen. After the reaction, the solvent was removed and the crude product was separated by column chromatography to obtain 1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl trifluoromethanesulfonate (45.0 g, 68% yield) as a pale yellow solid. LCMS (ESI): m / z 381.32 [M+1] + .
[0267] Step 1: Preparation of 5,6-bis(bromomethyl)isoindolin-1-one:
[0268] Dissolve 5,6-dimethylisoindolin-1-one (9.7 g, 60 mmol) and NBS (32.2 g, 180 mmol) in chloroform (120 mL). Heat the reaction to 80°C, then add dibenzoyl peroxide (336 mg, 1.2 mmol). Reaction is continued at 80°C for 8 h. TLC (PE:EA=5:1, R f =0.4), the reaction was completed and cooled to room temperature. The combined filtrate was then washed with saturated aqueous NaHCO3 (50 ml) and brine (50 ml), dried over MgSO4, and concentrated by filtration and rotary evaporation to give crude 5,6-bis(bromomethyl)isoindolin-1-one (11.44 g, 60%). LCMS: [M+H]+ =317.91.
[0269] Step 2: Preparation of 6-trityl-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-1(2H)-one:
[0270] To a solution of 5,6-bis(bromomethyl)isoindolin-1-one (11.44 g, 36 mmol) in DMF (100 mL) was added DIEA (16 mL, 92 mmol), followed by triphenylmethylamine (9.4 g, 36 mmol). The reaction mixture was stirred at 60°C for 4 hours, then poured into H₂O (400 mL) and stirred vigorously for 15 minutes. The precipitate was filtered and rinsed with H₂O (200 mL x 2). The combined filtrates were then dissolved and extracted with EA (3 x 200 mL). The combined organic layers were washed with water (3 x 50 mL) and brine (2 x 50 mL), dried over MgSO₄, and concentrated. Flash column chromatography (silica gel, DCM:EtOAc 50:1 to 20:1) afforded 6-trityl-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-1(2H)-one as a white solid (8.1 g, 54% yield). LCMS: [M+H] + =417.19.
[0271] Step 3: Preparation of 3-(1-oxo-6-trityl-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione:
[0272] Dissolve the raw material 6-trityl-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-1(2H)-one (8 g, 19.2 mmol) in THF (60 mL), then add t-BuOK (2.6 g, 23 mmol). React at 0°C for 0.5 h. Then, dissolve 1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl trifluoromethanesulfonate (8.6 g, 23 mmol) in THF (30 mL) and slowly add it to the reaction mixture. Continue reacting at 20°C for half an hour. After completion, quench the reaction with saturated ammonium chloride (80 mL) and extract with EA (200 mL). The combined organic phases are washed with saturated brine, dried, filtered, and concentrated. The crude product was purified by reverse HPLC (0.1% EA) to give 3-(1-oxo-6-trityl-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione as a yellow solid (5.66 g, 56% yield). LCMS: [M+H] + =528.22.
[0273] Step 4: Preparation of 3-(1-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione
[0274] Dissolve 3-(1-oxo-6-trityl-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (5.66 g, 10.8 mmol) in TfOH (8 mL) and react at 65°C for 4 h. After the reaction, concentrate the mixture and adjust the pH to between 6 and 7 with TEA at 0°C. Continue concentrating the mixture and add EA (200 mL) and stir for half an hour. Filter and dry to obtain 3-(1-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (2.2 g, 72% yield) as a white solid. LCMS: [M+H] + =286.11.
[0275] Preparation of E3L-7:2-(2,6-dioxopiperidin-3-yl)-6,7-dihydropyrrolo[3,4-f]isoindole-1,3(2H,5H)-dione:
[0276] Step 1: Preparation of 2-(1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl)-5,6-dimethylisoindoline-1,3-dione:
[0277] To a solution of 5,6-dimethylisobenzofuran-1,3-dione (3.52 g, 20 mmol) in acetic acid (40 mL) were added sodium acetate (3.28 g, 40 mmol) and 3-amino-1-(4-methoxybenzyl)piperidine-2,6-dione (4.96 g, 20 mmol). The mixture was stirred at 100 ° C for 12 hours. The reaction mixture was concentrated under reduced pressure to remove most of the acetic acid. The residue was poured into water (200 mL) and stirred for 15 minutes. The mixture was filtered. The filter cake was washed with water (50 mL × 2) and dried to give 2-(1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl)-5,6-dimethylisoindoline-1,3-dione (6.51 g, 80% yield) as an off-white solid. LC-MS: [M+H] + = 407.
[0278] Step 2: 5,6-bis(bromomethyl)-2-(1-(4-methoxybenzyl)-2,6-dioxapiperidin-3-yl)isoindoline-1,3-dione
[0279] 2-(1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl)-5,6-dimethylisoindoline-1,3-dione (6.51 g, 16 mmol) and NBS (8.58 g, 48 mmol) were dissolved in chloroform (50 mL). The reaction was heated to 80°C, followed by the addition of dibenzoyl peroxide (112 mg, 0.4 mmol) and the reaction was continued at 80°C for 8 h. After cooling to room temperature, the combined filtrate was washed with saturated aqueous NaHCO₃ (50 mL) and brine (50 mL), dried over MgSO₄, concentrated, filtered, and evaporated to afford crude 5,6-bis(bromomethyl)-2-(1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (4.95 g, 55%). LCMS: [M+H]⁺ = 563.
[0280] Step 3: Preparation of 2-(2,6-dioxopiperidin-3-yl)-6-trityl-6,7-dihydropyrrolo[3,4-f]isoindole-1,3(2H,5H)-dione:
[0281] To a solution of 5,6-bis(bromomethyl)-2-(1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (4.95 g, 8.8 mmol) in DMF (50 mL) was added DIEA (4.6 mL, 26.4 mmol), followed by triphenylmethane (2.3 g, 8.8 mmol). The reaction mixture was stirred at 60°C for 4 hours, then poured into H2O (200 mL) and stirred vigorously for 15 minutes. The precipitate was filtered and rinsed with H2O (100 mL x 2). The combined filtrates were then dissolved and extracted with EA (3 x 100 mL). The combined organic layers were washed with brine (2 x 50 mL), dried over MgSO4, and concentrated. Flash column chromatography (silica gel, DCM formula EA 50:1 to 20:1) afforded 2-(2,6-dioxopiperidin-3-yl)-6-trityl-6,7-dihydropyrrolo[3,4-f]isoindole-1,3(2H,5H)-dione (2.14 g, 45% yield). LCMS: [M+H] + =542.2.
[0282] Step 4: Preparation of 2-(2,6-dioxopiperidin-3-yl)-6,7-dihydropyrrolo[3,4-f]isoindole-1,3(2H,5H)-dione:
[0283] Dissolve the starting material, 2-(2,6-dioxopiperidin-3-yl)-6-trityl-6,7-dihydropyrrolo[3,4-f]isoindole-1,3(2H,5H)-dione (2.14 g, 3.96 mmol), in TfOH (3.3 mL) and react at 65°C for 4 h. After concentration, adjust the pH to 6-7 with TEA at 0°C. Continue concentrating the solution, then add EA (50 mL) and stir for half an hour. Filtration and drying afforded 2-(2,6-dioxopiperidin-3-yl)-6,7-dihydropyrrolo[3,4-f]isoindole-1,3(2H,5H)-dione (416 mg, 35%) as a white solid. LCMS: [M+H]+ = 300.1.
[0284] Preparation of E3L-8 piperidine hydrochloride: 1-(1-methyl-6-(piperidin-4-yl)-1H-indol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione hydrochloride:
[0285] Step 1: Preparation of methyl 3-[(6-bromo-1-methyl-1H-indazol-3-yl)amino]propanoate:
[0286] To a mixture of 6-bromo-1-methyl-1H-indazol-3-amine (3 g, 13.2 mmol) (prepared by mixing an equimolar mixture of DBU and lactic acid under stirring at room temperature for 16 hours, 1.5 g, 10.6 mmol) was added methyl acrylate (9.9 g, 98 mmol) in 5 portions (2.0 g per portion at 24 hour intervals) at 80 ° C. After completion, the reaction mixture was quenched with sodium hypochlorite (30% aqueous solution, 5 mL) and diluted with ethyl acetate. The organic matter was combined, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EA / PE=1:1) to give methyl 3-[(6-bromo-1-methyl-1H-indazol-3-yl)amino]propanoate (2.0 g, yield 45%). LCMS: [M+H] + =327.12.
[0287] Step 2: Preparation of 3-[(6-bromo-1-methyl-1H-indazol-3-yl)amino]propionamide:
[0288] Methyl 3-((6-bromo-1-methyl-1H-indazol-3-yl)amino)propanoate (2.0 g, 6.1 mmol) was dissolved in methanolic ammonia (20 ml, 5 mol / L) and stirred at room temperature for 24 h. The mixture was concentrated under reduced pressure to give the crude product 3-[(6-bromo-1-methyl-1H-indazol-3-yl)amino]propanamide (1.63 g, 90%), which was used directly in the next reaction. LCMS: [M+H] + =297.
[0289] Step 3: Preparation of 1-(6-bromo-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione:
[0290] To a solution of 3-((6-bromo-1-methyl-1H-indazol-3-yl)amino)propanamide (1.63 g, 5.59 mmol) in THF (30 mL) were added triphosgene (780 mg, 2.8 mmol) and DIEA (1.44 g, 11.2 mmol). The mixture was stirred at 80 ° C for 12 h, cooled to room temperature, quenched with saturated NH4Cl aqueous solution (50 mL), extracted with EA (50 mL×3), and the organic matter was combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EA / PE=1:1) to give 1-(6-bromo-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (1.26 g, yield 70%). LCMS: [M+H] + =324.
[0291] Step 4: Preparation of tert-butyl 4-[3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl]-3,6-dihydropyridine-1(2H)-carboxylate:
[0292] To a solution of 1-(6-bromo-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (1.26 g, 3.88 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (2.43 g, 7.76 mmol) in 1,4-dioxane (20 mL) was added cesium fluoride (1.20 g, 7.76 mmol) and Pd(dppf)Cl2 (570 mg, 776 μmol), and the mixture was stirred at 85°C for 3 hours under a nitrogen atmosphere. The mixture was cooled to room temperature, diluted with ethyl acetate (50 mL), and filtered through celite / silica gel. After washing with ethyl acetate (20 mL), the filtrate was washed with water, the organic layers were combined, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography (EA:PE=10:1) to give 4-[3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl]-3,6-dihydro-pyridine-1(2H)-carboxylic acid tert-butyl ester (990 mg, 2.44 mmol, yield 60%). LCMS: [M+H] + =426.3.
[0293] Step 5: Preparation of tert-butyl 4-[3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl]piperidine-1-carboxylate:
[0294] To a solution of tert-butyl 4-[3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl]-3,6-dihydro-pyridine-1(2H)-carboxylate (990 mg, 2.32 mmol) in methanol (20 mL) was added palladium (10% on carbon, 1.0 g, 0.94 mmol). The mixture was stirred at room temperature under a hydrogen balloon atmosphere for 24 hours. The reaction mixture was filtered through celite and washed with a mixture of dichloromethane (20 mL x 3). The combined washings were concentrated under reduced pressure to give tert-butyl 4-[3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl]piperidine-1-carboxylate (829 mg, 95% yield). LCMS: [M+H]+ = 427.
[0295] Step 6: Preparation of 1-(1-methyl-6-(piperidin-4-yl)-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione hydrochloride: tert-Butyl 4-[3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl]piperidine-1-carboxylate
[0296] 4-[3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl]piperidine-1-carboxylic acid tert-butyl ester (829 mg, 2.2 mmol) and hydrochloric acid (4M, 2.6 mL) were stirred in ethyl acetate (10 mL) overnight. The resulting mixture was concentrated under reduced pressure. The residue was washed with ethyl acetate (5x20 mL) and slurried. 1-(1-methyl-6-(piperidin-4-yl)-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione hydrochloride (720 mg, yield 90%) was obtained. LCMS: [M+H] + =328.2.
[0297] E3L-9 diflupiperidine hydrochloride:
[0298] Synthesis of 1-(6-(3,3-difluoropiperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione hydrochloride according to the embodiment of E3L-8 difluoropiperidin hydrochloride LCMS: [M+H] + =364.1.
[0299] E3L-10 Piperazine hydrochloride: 1-(6-(3,3-difluoropiperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione hydrochloride was synthesized according to the embodiment of E3L-8. LCMS: [M+H] + =347.
[0300] Preparation of E3L-11 piperazine hydrochloride: 2-(2,6-dioxopiperidin-3-yl)-2-fluoro-4-(piperazin-1-yl)benzamide hydrochloride:
[0301] Step 1: Preparation of 1-tert-butyloxycarbonyl-4-(3-fluoro-4-methoxyformylphenyl)piperazine:
[0302] Methyl 2-fluoro-4-bromobenzoate (3 g, 12.9 mmol) was dissolved in toluene (30 mL), and 1-Boc-piperazine (2.87 g, 15.5 mmol), palladium acetate (145 mg, 0.645 mmol), BINAP (803 mg, 1.29 mmol), and cesium carbonate (8.46 g, 25.8 mmol) were added. The reaction was stirred at 80°C overnight. After the reaction was complete, the temperature was lowered to room temperature, the toluene was removed by rotary evaporation, 100 mL of ethyl acetate was added, and the mixture was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EA / PE = 1:5) to obtain 1-tert-butyloxycarbonyl-4-(3-fluoro-4-methoxyformylphenyl)piperazine (3.0 g, yield 69%). LCMS: [M+H] + =339.
[0303] Step 2:1: Preparation of tert-butyl 4-(3-fluoro-4-carboxyphenyl)piperazine-1-carboxylate:
[0304] 1-tert-Butyloxycarbonyl-4-(3-fluoro-4-methoxyformylphenyl)piperazine (3.0 g, 8.88 mmol) was dissolved in THF (20 ml L), and an aqueous solution of lithium hydroxide (852 mg, 35.5 mol) was added. The mixture was stirred at room temperature for 2 h. After completion of the reaction, the pH was adjusted to 6-7, and the mixture was extracted with EA (50 mL x 3). The combined organic phases were washed with brine, dried, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EA / PE = 1:1) to give tert-butyl 4-(3-fluoro-4-carboxyphenyl)piperazine-1-carboxylate (2.5 g, 87%). LCMS: [M+H] + =352.
[0305] Step 3: Preparation of 2-(2,6-dioxopiperidin-3-yl)-2-fluoro-4-(piperazine-(4-carboxylic acid tert-butyl ester)-1-yl)benzamide:
[0306] 4-(3-Fluoro-4-carboxyphenyl)piperazine-1-carboxylic acid tert-butyl ester (2.5 g, 7.72 mmol) was dissolved in DMF (30 mL), 3-amino-2,6-piperidinedione hydrochloride (1.27 g, 7.72 mmol), HATU (4.4 g, 11.58 mmol), DIEA (2.99 g, 23.16 mmol) were added, and the mixture was stirred at room temperature at 80 ° C for 12 h. After the reaction was completed, saturated NH4Cl aqueous solution (50 mL) was added to quench the reaction, and EA (50 mL×3) was added. The organic matter was combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EA / PE=1:5) to give 2-(2,6-dioxopiperidin-3-yl)-2-fluoro-4-(piperazine-(4-carboxylic acid tert-butyl ester)-1-yl)benzamide hydrochloride (1.7 g, yield 75%). LCMS: [M+H] + =435. Step 4: Preparation of 2-(2,6-dioxopiperidin-3-yl)-2-fluoro-4-(piperazin-1-yl)benzamide hydrochloride:
[0307] 2-(2,6-dioxopiperidin-3-yl)-2-fluoro-4-(piperazine-(4-carboxylic acid tert-butyl ester)-1-yl)benzamide (1.7 g, 3.92 mmol) was dissolved in ethyl acetate (25 mL) and a hydrochloric acid solution of ethyl acetate was added. The mixture was stirred at room temperature for 1 hour. After the reaction, the solvent was removed by concentration, and the residue was washed twice with diethyl ether and dried to give 2-(2,6-dioxopiperidin-3-yl)-2-fluoro-4-(piperazin-1-yl)benzamide (1.1 g, yield 84.6%). LCMS: [M+H] + =335.
[0308] E3L-12 Piperazine hydrochloride: N-(2,6-dioxopiperidin-3-yl)-4-(piperazin-1-yl)benzamide hydrochloride was synthesized according to the method of E3L-11. LCMS: [M+H] + =317.
[0309] E3L-13 Piperazine hydrochloride: N-(2,6-dioxo-piperidin-3-yl)-4-(piperazin-1-yl)-2-pyridineamide hydrochloride was synthesized according to the method of E3L-12. LCMS: [M+H] + =317.
[0310] Example 1
[0311] Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(3-((4-(4-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)phenyl)piperazin-1-yl)methyl)azetidin-1-yl)isoindoline-1,3-dione (Compound 1):
[0312] Step 1: Preparation of tert-butyl 4-(4-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)phenyl)piperazine-1-carboxylate:
[0313] To a solution of 5-((4-chlorophenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole (300 mg, 0.62 mmol) in THF (50 mL) were added tert-butylpiperazine-1-carboxylate (173.5 mg, 0.93 mmol), RuPhos (58.0 mg, 0.12 mmol), RuPhos Palladacycle G3 (103.9 mg, 0.12 mmol), t-BuONa (179.1 mg, 1.86 mmol) and THF (5 mL). The resulting mixture was stirred at 85 ° C. overnight. Water (2 mL) was added to quench the reaction at room temperature. The resulting mixture was extracted with ethyl acetate (3×10 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EA (5:1) to provide tert-butyl 4-(4-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-methylene)methyl)phenyl)piperazine-1-carboxylate (145 mg, 36.89%) as a white solid. LCMS (ESI): m / z 633.22 [M+1] + .
[0314] Step 2: Preparation of 3-fluoro-5-((4-(piperazin-1-yl)phenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)-1H-indazole:
[0315] To a solution of tert-butyl 4-(4-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)phenyl)piperazine-1-carboxylate (145 mg, 0.23 mmol) in DCM (0.5 mL) was added TFA (1.5 mL). The resulting mixture was stirred at room temperature for 12 hours. The resulting mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (2 mL). The mixture was basified to pH 10 with K2CO3 and the resulting mixture was extracted with EtOAc (3×2 mL). The combined organic layers were dried over anhydrous sodium sulfate, and the filtered filtrate was concentrated under reduced pressure. The residue was purified by preparative thin-layer chromatography (DCM / MeOH 5:1) to afford 3-fluoro-5-((4-(piperazin-1-yl)phenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1H-indazole (80 mg, 77.83%) as a white solid. After filtration, the filtrate was concentrated under reduced pressure. LCMS (ESI): m / z 449.3 [M+1] + .
[0316] Step 3: Preparation of tert-butyl 3-((4-(4-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)phenyl)piperazin-1-yl)methyl)azetidine-1-carboxylate:
[0317] To a solution of 3-fluoro-5-((4-(piperazin-1-yl)phenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1H-indazole (80 mg, 0.18 mmol) in MeOH (0.5 mL) was added tert-butyl 3-formylmonoheterocyclobutane-1-carboxylate (66.1 mg, 0.36 mmol) at room temperature for 1 hour, and then NaBH3CN (22.4 mg, 0.36 mmol) was added dropwise at 0°C. The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water at room temperature. The resulting mixture was concentrated under vacuum. The resulting mixture was extracted with EtOAc (3X2 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative thin-layer chromatography (PE / EA 1:1) to give tert-butyl 3-((4-(4-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)phenyl)piperazin-1-yl)methyl)azetidine-1-carboxylate (80 mg, 72.61%) as a white solid. LCMS (ESI): m / z 618.4 [M+1] + .
[0318] Step 4: Preparation of 5-((4-(4-(azetidin-3-ylmethyl)piperazin-1-yl)phenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-3-fluoro-1H-indazole:
[0319] To a solution of tert-butyl-3-((4-(4-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)phenyl)piperazin-1-yl)methyl]azetidine-1-carboxylate (80 mg, 0.13 mmol) in DCM (0.9 mL) was added TFA (0.3 mL, 4.04 mmol). The resulting mixture was stirred at room temperature for 12 hours. The resulting mixture was concentrated under reduced pressure. After filtration, the filtrate was concentrated under reduced pressure. 5-((4-(4-(azetidin-3-ylmethyl)piperazin-1-yl)phenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-3-fluoro-1H-indazole (60 mg, 94.63%) was obtained as a yellow oily liquid. The crude product was used directly in the next reaction without further purification. LCMS (ESI): m / z 518.32[M+1] + .
[0320] Step 5: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(3-(4-(4-(3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)phenyl)piperazin-1-yl)methyl)azetidin-1-yl)isoindoline-1,3-dione (Compound 1):
[0321] 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (E3L-1) (293.5 mg, 1.06 mmol) and DIEA (312.1 mg, 2.42 mmol) were added to a solution of {4-[4-(azetidin-3-methyl)piperazine-1-yl]phenyl}(2,2,6,6-tetramethoxy-4-ylmethylene)methyl)-3-fluoro-1H-indazole (250 mg, 0.48 mmol) in DMSO (4 mL). The resulting mixture was stirred at 100 ° C for 12 hours. Water (2 mL) was added at room temperature to quench the reaction. The resulting mixture was extracted with ethyl acetate (3×5 mL). The combined organic layer was washed with water (3×3 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse flash chromatography under the following conditions: column: Xselect CSH C18 OBD column 30X150 mm 5 μm, n; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 24% B to 53% B in 10 minutes, 53% B; wavelength: 254 nm; RT1 (minutes): 8.63. 2-(2,6-dioxopiperidin-3-yl)-5-(3-(4-(4-(3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)phenyl)piperazin-1-yl)methyl)azetidin-1-yl)isoindoline-1,3-dione (Compound 1) LCMS (ES, m / z): 774.4 [M+H] +; (27.8 mg, 7.44%) was obtained as a yellow solid. 1H NMR (DMSO, 400MHz) δ (ppm): 12.54 (s, 1H), 11.10 (s, 1H), 9.86 (s, 1H), 7.70-7.68 (d, J = 8.4Hz, 1H), 7.45-7.41 (m ,2H),7.21-7.20(d,J=1.6Hz,1H),7.13-7.11(d,J=8.4Hz,2H),6.97-6.95(d,J=8.8Hz,2H),6.82(s,1H),6.70-6 .67(d,J=10.4Hz,1H),5.06(m,1H),4.28-4.23(m,2H),3.88-3.82(m,4H),3.56-3.54(s,4H),3.31(m,1H),3.16- 3.14(m,2H),3.00(m,3H),2.60(s,1H),2.50-2.49(d,J=1.6Hz,4H),2.21(m,1H),1.17-1.12(d,J=17.2Hz,12H).
[0322] According to the synthetic route of compound 1, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are as described in Example 1 above, but the molar masses of the starting compounds and intermediates were kept unchanged):
[0323] Example 2: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(3-(4-(4-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-ylmethylene)methyl)phenyl)piperazin-1-yl)azetidin-1-yl)isoindazole-1,3-dione (Compound 2):
[0324] Step 1: Preparation of tert-butyl 3-(4-(4-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)phenyl)piperazin-1-yl)azetidine-1-carboxylate:
[0325] To a solution of 5-((4-chlorophenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole (300 mg, 0.6 mmol) in THF (5 mL) were added tert-butyl 3-(piperazin-1-yl)azetidine-1-carboxylate (450 mg, 1.8 mmol), RuPhos Palladacycle G3 (104 mg, 0.12 mmol), RuPhos (58 mg, 0.12 mmol) and t-BuONa (179 mg, 1.8 mmol), and the resulting mixture was stirred at 85 ° C. under a nitrogen atmosphere overnight. The reaction was quenched with water at room temperature. The resulting mixture was extracted with EA (3x20 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography (DCM / MeOH 10:1) to give tert-butyl 3-(4-(4-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl](2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)phenyl)piperazin-1-yl]azetidine-1-carboxylate (200 mg, 46.81%) as a yellow oil. LCMS (ES, m / z): 688 [M+H] + .
[0326] Step 2: Preparation of 5-((4-(4-(azetidin-3-yl)piperazin-1-yl)phenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)-3-fluoro-1H-indazole:
[0327] To a solution of tert-butyl 3-(4-(4-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)phenyl)piperazin-1-yl)azetidine-1-carboxylate (180 mg, 0.3 mmol) in DCM (8 mL) was added TFA (2 mL) and the mixture was stirred at room temperature under nitrogen atmosphere. The reaction mixture was stirred overnight. The resulting mixture was concentrated under reduced pressure. 5-((4-(4-(azetidin-3-yl)piperazin-1-yl)phenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-3-fluoro-1H-indazole (110 mg, 83.46%) was obtained as a yellow oil. The crude product was used directly in the next step without further purification. LCMS (ES, m / z): 504 [M+H] + .
[0328] Step 3: Preparation of 2-(2,6-dioxopiperidin-3-yl)-5-(3-(4-(4-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)phenyl)piperazin-1-yl)azetidin-1-yl)isoindoline-1,3-dione:
[0329] To a stirred solution of 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (121 mg, 0.4 mmol) in DMSO (1 mL) of 5-((4-(4-(azetidin-3-yl)piperazin-1-yl)phenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole (100 mg, 0.2 mmol) was added DIEA (128 mg, 1.0 mmol). The resulting mixture was stirred at 100 ° C. for 4 hours under a nitrogen atmosphere. The reaction was quenched with water at room temperature. The resulting mixture was extracted with EA (3x20 mL). The combined organic layers were washed with water (3x5 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by thin layer chromatography (DCM / MeOH 10:1) to give a yellow solid. The crude product (100 mg) was purified by Prep-HPLC using the following conditions (column: Xselect CSH C18 OBD column 30*150 mm 5 μm, n; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 30% B to 59% B in 7 minutes, 59% B; wavelength: 254 nm; RT1 (minute): 5.25; number of operations: 0) to give 2-(2,6-dioxopiperidin-3-yl)-5-(3-(4-(4-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)phenyl)piperazin-1-yl)azetidin-1-yl)isoindazolin-1,3-dione (90.5 mg, 59.51%) as a yellow solid. LCMS (ES, m / z): 760 [M+H] + ;1H NMR (400MHz, DMSO-d6) δ (ppm): 12.53 (s, 1H), 11.10 (s, 1H), 7.75-7.73 (d, J = 8.0Hz, 1H), 7. 45-7.41(m,2H),7.29-7.27(m,1H),7.21-7.18(m,1H),7.12-7.08(m,2H),6.98-6.91(m,3H) ,6.77-6.75(m,1H),5.10-5.06(m,1H),4.36-4.30(m,4H),3.91-2.84(m,9H),2.61-2.55(m, 2H), 2.50-2.14 (d, J = 27.2Hz, 4H), 2.89-2.86 (m, 1H), 2.05-2.0 (m, 1H), 1.17-1.10 (m, 12H).
[0330] According to the synthetic route of compound 2, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are referred to the above Example 2, but the molar masses of the starting compounds and intermediates were controlled to remain unchanged):
[0331] Example 3: Preparation of 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 34):
[0332] Step 1: Preparation of (1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl}pyridin-2-yl)piperidin-4-yl)methanol:
[0333] To 3-fluoro-5-((6-fluoropyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole (400 mg, 0.9 mmol) and piperidine-4-methanol (296 mg, 2.6 mmol) in DMSO (5 mL) was added K2CO3 (591 mg, 4.5 mmol) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 130°C under nitrogen atmosphere overnight. The resulting mixture was extracted with ethyl acetate (3x20 mL). The combined product was purified by HPLC. The organic layer was washed with water (3x5mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and then eluted with PE / EA (3:1) to give (1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methanol (400mg, 83.09%) as butter. LCMS (ES, m / z): 563[M+H] + .
[0334] Step 2: Preparation of 1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)piperidine-4-carbaldehyde:
[0335] To a solution of (1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl}pyridin-2-yl)piperidin-4-yl)methanol (350 mg, 0.6 mmol) in DCM (3 mL) was added Dess-Martin (174 mg, 0.4 mmol) at 0°C under nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with DCM (3 x 20 mL). The filtrate was concentrated under reduced pressure. The residue was purified by thin layer chromatography (DCM / MeOH). 9:1) was purified to give 1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidine-4-carbaldehyde (200 mg, 57.35%) as yellow oil. LCMS (ES, m / z): 561 [M+H] + .
[0336] Step 3: Preparation of 3-(5-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl](2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione:
[0337] To a stirred solution of 1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidine-4-carbaldehyde (100 mg, 0.2 mmol) in DCE (2 mL) was added a hydrochloric acid solution of 3-[1-oxo-5-(piperazin-1-yl)-3H-indol-2-yl]piperidine-2,6-dione (70 mg, 0.2 mmol) and STAB (76 mg, 0.4 mmol) was added at room temperature. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was quenched with water. The resulting mixture was extracted with DCM (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. 3-(5-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 64.22%) was purified by pre-thin layer chromatography (PE / EA 1:1) as a yellow oil. LCMS (ES, m / z): 873 [M+H] +.
[0338] Step 4: Preparation of 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindol-2-yl)piperidine-2,6-dione (Compound 34):
[0339] In a 50 mL round-bottom flask was added 3-(5-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (120 mg, 0.14 mmol), DCM (8 mL) and TFA (2 mL). The resulting mixture was stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC using the following conditions (column: Xselect CSH C18 OBD column 30*150mm 5μm, n; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 16% B to 36% B in 7 minutes, 36% B; wavelength: 254 nm; RT1 (minute): 5.68; number of operations: 0) to give 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (74.1 mg, 67.79%) as a white solid. LCMS (ES, m / z): 789 [M+H] +;1H NMR (400MHz, DMSO-d6) δ (ppm): 12.58 (s, 1H), 10.99 (s, 1H), 9.49 (s, 1H), 7.97-7.96 (d, J = 2.4Hz, 1H), 7.61-7.60 (d, J = 8.4Hz, 1 H),7.53-7.44(m,3H),7.26-7.16(m,3H),7.00-6.99(d,J=6.8Hz,1H),5.10-5.05(m,1H),4.39-4.34(d,J=17.2Hz,2H),4.28-4 .22(m,3H),4.03-4.00(d,J=10.0Hz,3H),3.65-3.63(d,J=8.4Hz,2H),3.24-3.12(m,5H),2.95-2.88(m,3H),2.62-2.58(d,J=1 6.4Hz,1H),2.41-2.34(m,1H),2.24(s,2H),2.16(s,2H),1.97-1.93(m,1H),1.86-1.84(d,J=12.3Hz,2H),1.23-1.13(m,12H).
[0340] Step 5: Preparation of (R) 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 119) and (S) 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 110):
[0341] 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 34) (50 mg) Chiral HPLC column CHIRAL-HPLC: Column: JW-CHIRAL ART cellulose-SB, 4.6*100 mm; 3 μm; Mobile phase A: Hex (0.1A): (IPA:DCM = 1:2) = 50:50; Flow rate: 1 mL / min; Gradient: 0% B to 0% B; Injection volume: 5 μl ml, used to prepare (S) 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (11 mg) as a white solid. LCMS (ES, m / z): 815 [M+H] + Chiral high performance liquid chromatography: Rt = 1.225; and (R) 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 119) (14.2 mg) as a white solid. LCMS (ES, m / z): 815 [M+H] + ; Chiral HPLC: Rt=1.769.
[0342] According to the synthetic route of compound 34, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are referred to the above Example 3, but the molar masses of the starting compounds and intermediates were controlled to remain unchanged):
[0343] Example 4: (R)-3-(5-(4-(7-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-yl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 121) and (S)-3-(5-(4-(7-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]non-2-yl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 120):
[0344] Step 1: Preparation of 7-(5-(3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-one:
[0345] To a solution of 3-fluoro-5-((6-fluoropyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-indole (300 mg, 0.642 mmol, 1 eq) in DMSO (5 mL) and 7-azaspiro[3.5]nonan-2-one (267.94 mg, 1.926 mmol, 3 eq) was added K2CO3 (266.03 mg, 1.926 mmol, 3 eq) at room temperature. The final reaction mixture was stirred at room temperature. Irradiate with microwaves at 130 ° C overnight. The reaction is quenched with water at room temperature. The resulting mixture is extracted with ethyl acetate and dried over anhydrous sodium sulfate. After filtration, the filtrate is concentrated under reduced pressure. The residue is purified by preparative thin layer chromatography (PE / EA) to give 7-(5-(3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-one (160 mg, 42.50%). LCMS (ES, m / z): 587 [M+H] + .
[0346] Step 2: Preparation of a mixture of 7-(5-(3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-one:
[0347] To 7-(5-(3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-one (160 mg, 0.273 mmol) DCM (2 mL) was added TFA (1 mL, 13.463 mmol, 49.37 equiv) and stirred at room temperature overnight. The resulting mixture was concentrated under vacuum. 7-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-one (160 mg, 93.39%) was obtained as a brown oil. LCMS (ES, m / z): 503 [M+H] + .
[0348] Step 3: Preparation of 3-(5-(4-(7-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-yl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 35):
[0349] 7-(5-((3-Fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-one (150 mg, 0.298 mmol, 1 eq) and 3-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione (146.99 mg, 0.447 mmol, 1.5 eq) in DCM and DMF were treated with NaOAc (122.41 mg, 1.490 mmol, 5 eq) at room temperature for 2 hours, followed by the addition of STAB (126.50 mg, 0.596 mmol, 2 eq) dropwise / portionally at room temperature. The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water. The resulting mixture was extracted with ethyl acetate and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The crude product (100 mg) was purified by Prep-HPLC using the following conditions (column: Sunfire (Waters), 30*150 mm, 5 μm; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 21% B to 35% B in 8 minutes, 35% B; wavelength: 254 nm; RT1 (minute): 7.73; number of operations: 0) to give 3-(5-(4-(7-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-yl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (15.6 mg, 6.40%) as a white solid. LCMS (ES, m / z):815[M+H]+; 1H NMR(400MHz,DMSO-d6)δ(ppm):12.54(s,1H),10.98(s,1H),7.91(s,1H),7.60(d,1H),7.56-7.40(m ,3H),7.26-7.12(m,3H),6.98(s,1H),4.41-4.33(d,1H),4.30-4.19(d,1H),4.11-4.01(d,2H),3.91 -3.83(d,1H),3.58-3.40(m,6H),3.17-3.08(m,1H),3.08-2.89(m,3H),2.62-2.54(m,1H),2.43-2.3 5(m,1H),2.26-2.21(m,4H),2.19(s,2H),2.12-2.08(m,2H),2.04-1.98(m,1H),1.18-1.13(d,12H).
[0350] Step 4: (R) 3-(5-(4-(7-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-yl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 121) ) and (S)-3-(5-(4-(7-(5-(3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-methylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-yl)piperazin-1-yl)-1-oxoisoindol-2-yl)piperidine-2,6-dione (Compound 120):
[0351] 3-(5-(4-(7-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-yl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 35) (50 mg) CHIRAL-HPLC: Column: JW-CHIRAL ART Cellulose-SB, 4.6*100 mm; 3 μm; Mobile phase A: Hex (0.1A): (IPA:DCM=1:2)=50:50; Flow rate: 1 mL / min; Gradient: 0% B to 0% B; Injection volume: 5 μl M1, used to prepare (S) 3-(5-(4-(7-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-yl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 120) (5.0 mg, 9.61%) as a white solid. LCMS (ES, m / z): 815 [M+H] + Chiral high performance liquid chromatography: Rt = 3.269; and (R) 3-(5-(4-(7-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-7-azaspiro[3.5]nonan-2-yl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 121) (4.2 mg, 7.98%) as a white solid. LCMS (ES, m / z): 815 [M+H] + ; Chiral high performance liquid chromatography: Rt=4.556.
[0352] According to the synthetic routes of compounds 120 and 121, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are as described in Example 4 above, but the molar masses of the starting compounds and intermediates were kept unchanged):
[0353] Example 5: Preparation of 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 36):
[0354] Step 1: Preparation of 1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-4-(hydroxymethyl)piperidin-4-ol
[0355] To a solution of 3-fluoro-5-((6-fluoropyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole (800 mg, 1.7 mmol) in DMSO (5 mL) was added 4-(hydroxymethyl)piperidin-4-ol (449 mg, 3.4 mmol) and DIEA (1106 mg, 8.6 mmol). The resulting mixture was stirred at 110° C. under a nitrogen atmosphere overnight. The reaction was quenched with water at room temperature and the resulting mixture was washed with ethyl acetate (3×20 The mixture was extracted with 4% paraformaldehyde (5-nitropropane) (4-nitropropane-2-yl)propanediol (2-nitropropane-3-yl)propanediol (2-nitropropane-4-yl)propanediol (3-nitropropane-5-yl)propanediol (2-nitropropane-3 ... + .
[0356] Step 2: Preparation of 1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidine-4-carbaldehyde:
[0357] 1-(5-((3-Fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-4-(hydroxymethyl)piperidin-4-ol (100 mg, 0.17 mmol) was added to a stirred solution in dimethyl sulfoxide (2 mL) and IBX (194 mg, 0.7 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 4 hours. The reaction was quenched with water at room temperature. The resulting mixture was extracted with EtOAc (3x20 mL). The combined organic layers were washed with water (3x5 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. 1-(5-((3-Fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidine-4-carbaldehyde (50 mg, 50.17%) was obtained as an off-white solid. LCMS (ES, m / z): 577 [M+H] + .
[0358] Step 3: Preparation of 3-(5-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione:
[0359] To a stirred solution of 1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidine-4-carbaldehyde (180 mg, 0.31 mmol) in DCM / DMF were added: 3-(1-oxo-5-(piperazin-1-yl)isoindol-2-yl)piperidine-2,6-dione (0.5 mg, 0.62 mmol) and STAB (132.30 mg, 0.62 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water at room temperature. The resulting mixture was extracted with DCM (3 x 10 mL). The combined organic layers were washed with water (3 x 5 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. 3-(5-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (150 mg, 54.05%) was obtained as a yellow oil. LCMS (ES, m / z): 889 [M+H] + .
[0360] Step 4: Preparation of 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 36):
[0361] To a solution of 3-(5-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4yl)-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (150 mg, 0.17 mmol) in DCM (6 mL) was added TFA (1.5 mL), and the mixture was stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure. The crude product (100 mg) was purified by Prep-HPLC using the following conditions (column: Xselect CSH C18 OBD (Waters) column 30x150 mm 5 μm, n; mobile phase A: water (0.1% TFA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 11% B to 41% B in 7 minutes; wavelength: 254 nm; RT1 (min): 5.89) to give 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 36) (23.4 mg, 17.06%) as a white solid. LCMS (ES, m / z): 805 [M+H] + ;1H NMR (400MHz, DMSO-d6) δ (ppm): 12.56 (s, 1H), 10.97 (s, 1H), 9.37 (s, 1H), 7.98 (s, 1H), 7.61-7.58 (d, J = 8.4Hz, 1H), 7. 51-7.41(m,2H),7.25-7.22(m,1H),7.18-7.11(m,2H),6.99-6.96(d,J=13.2Hz,1H),5.45(s,1H),5.11-5.01(m,1H),4 .41-4.18(m,2H),3.98-3.81(m,4H),3.71-3.63(s,2H),3.45-3.17(m,7H),2.95-2.88(m,1H),2.69-2.53(m,1H),2.44 -2.36(m,1H),2.22(s,2H),2.15(s,1H),2.01-1.94(m,1H),1.81-1.73(m,2H),1.73-1.58(m,2H),1.19-1.01(m,12H).
[0362] According to the synthetic route of compound 36, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are shown in Example 5 above, but the molar masses of the starting compounds and intermediates were kept unchanged):
[0363] Example 6
[0364] Preparation of 3-(6-(1-((1-(5-(3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-1-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (Compound 69):
[0365] Step 1: Preparation of tert-butyl 4-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-1-carboxylate:
[0366] 3-(1-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindole-2(1H)-yl)piperidine-2,6-dione (143 mg, 0.5 mmol) STAB (213.30 mg, 1 mmol) was added to a stirred DMA (1 mL) solution of tert-butyl 4-oxopiperidine-1-carboxylate (100 mg, 0.5 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water at room temperature. The resulting mixture was extracted with DCM (3 x 10 mL). The combined organic layer was washed with water (3 x 5 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. Tert-butyl 4-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-1-carboxylate (281 mg, 60%) was obtained as a yellow oil. LCMS (ES, m / z): 469.55 [M+H] + .
[0367] Step 2: Preparation of 3-(1-oxo-6-(piperidin-4-yl)-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione:
[0368] To a solution of tert-butyl 4-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-1-carboxylate (281 mg, 0.3 mmol) in DCM (8 mL) was added TFA (2 mL), and the mixture was stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure, dissolved in DCM (20 mL), and washed with NaHCO (10 mL). The layers were separated, and the aqueous phase was extracted with DCM (3 x 10 mL). The combined organic layers were washed with water (3 x 5 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to obtain 3-(1-oxo-6-(piperidin-4-yl)-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (88 mg, 80%) as a yellow oily liquid. The crude product was used directly in the next step without further purification. LCMS (ES, m / z): 504 [M+H] + .
[0369] Step 3: Preparation of 3-(6-(1-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-1-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione:
[0370] To a stirred solution of 1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidine-4-carbaldehyde (134.5 mmol, 0.24 mmol) in DMA (1 mL) was added 3-(1-oxo-6-(piperidin-4-yl)-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (88 mmol, 0.24 mmol) and STAB (106 mg, 0.5 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water at room temperature. The resulting mixture was extracted with DCM (3 x 10 mL). The combined organic layers were washed with water (3 x 5 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. 3-(6-(1-(1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-1-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (131 mg, 60%) was obtained as a yellow oily liquid. LCMS (ES, m / z): 914.15 [M+H] + .
[0371] Step 4: Preparation of 3-(6-(1-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-1-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (Compound 69):
[0372] To a solution of 3-(6-(1-(1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-1-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (130 mg, 0.14 mmol) in DCM (1 mL) was added TFA (0.5 mL), and the mixture was stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure. The crude product (90 mg) was purified by Prep-HPLC using the following conditions (column: Xselect CSH C18 OBD column (Waters) 30x150 mm 5 μm, n; mobile phase A: water (0.1% TFA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 11% B to 41% B in 7 minutes; wavelength: 254 nm; RT1 (min): 5.89) to give 3-(6-(1-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-1-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (Compound 69) (35.4 mg, 30%) as a white solid. LCMS (ES, m / z): 829.45 [M+H] + ;1H NMR (400MHz, DMSO-d6) δ (ppm): 12.55 (s, 1H), 10.96 (s, 1H), 9.37 (s, 1H), 7.64-7.58 (d, J = 8.4Hz, 1H), 7.52-7.42 (m ,2H),7.26-7.22(m,1H),7.18-7.11(m,2H),6.99-6.96(d,J=13.2Hz,1H),5.45(s,1H),5.11-5.01(m,1H),4.41-4. 18(m,2H),3.98-3.81(m,4H),3.72-3.58(s,6H),3.45-3.17(m,3H),2.95-2.88(m,1H),2.69-2.52(m,2H),2.44-2. 36(m,1H),2.22(s,2H),2.15(s,1H),2.01-1.94(m,1H),1.84-1.73(m,4H),1.75-1.56(m,4H),1.22-1.04(m,12H).
[0373] Example 7: Preparation of 3-(6-(2-(7-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-oxoethyl)-1-oxo-3.5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (Compound 70):
[0374] Step 1: Preparation of tert-butyl 7-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-2,7-diazaspiro[3.5]nonane-2-carboxylate:
[0375] To a solution of 3-fluoro-5-((6-fluoropyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole (234 mg, 0.5 mmol) in DMSO (5 mL) was added tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate (136 mg, 0.6 mmol, 3 equivalents) and K2CO3 (208 mg, 1.5 mmol) was added at room temperature. The final reaction mixture was irradiated with microwaves at 130 ° C overnight. The reaction was quenched with water at room temperature. The resulting mixture was extracted with ethyl acetate and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative thin-layer chromatography (PE / EA) to give tert-butyl 7-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-2,7-diazaspiro[3.5]nonane-2-carboxylate (162 mg, 55%). LCMS (ES, m / z): 590.34, [M+H] + .
[0376] Step 2: Preparation of 7-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-2,7-diazaspiro[3.5]nonane:
[0377] To a solution of tert-butyl 7-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-2,7-diazaspiro[3.5]nonane-2-carboxylate (162 mg, 0.28 mmol) in DCM (4 mL) was added TFA (2 mL) and stirred overnight at room temperature under a nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure, dissolved in DCM (20 mL), washed with NaHCO3 (10 mL), and the layers were separated, and the aqueous phase was extracted with DCM (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to provide 7-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-2,7-diazaspiro[3.5]nonane (Compound 70-B) (114 mg, 85%) as a yellow oily liquid. The crude product was used directly in the next step without further purification. LCMS (ES, m / z): 490.28 [M+H] + .
[0378] Step 3: Preparation of tert-butyl 2-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetate:
[0379] To a stirred MeCN (30 mL) solution of 3-(1-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (1.43 g, 5 mmol) was added tert-butyl bromoacetate (1.07 g, 5.5 mmol) and DIEA (3.22 g, 25 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water at room temperature. The resulting mixture was extracted with DCM (3 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography and eluted with DCM / MeOH (20:1) to afford tert-butyl 2-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)carboxylate (1.6 g, 80%) as a yellow oil, which was used directly in the next reaction. LCMS (ES, m / z): 400.55 [M+H] + .
[0380] Step 4: Preparation of 2-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetic acid:
[0381] To a solution of tert-butyl 2-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)carboxylate (1.6 g, 4 mmol) in DCM (10 mL) was added TFA (10 mL) and stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure, dissolved in DCM (50 mL), washed with H₂O (50 mL), and separated. The aqueous phase was extracted with DCM (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to yield 2-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetic acid (1.16 g, 85%) as a yellow oil. The crude product was used directly in the next step without further purification. LCMS (ES, m / z): 342.28 [M+H]-.
[0382] Step 5: Preparation of 3-(6-(2-(7-(5-(3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)pyridin-2-yl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-oxoethyl)-1-oxo-3.5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione:
[0383] To a solution of 2-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetic acid (82 mg, 0.24 mmol) in DMA (2 mL) were added compound 70-B (114 mg, 0.24 mmol), HATU (137 mg, 0.36 mmol), and DIEA (62 mg, 0.48 mmol). The resulting mixture was stirred at room temperature under a nitrogen atmosphere overnight. The reaction was quenched with water (20 mL) and extracted with EA (4 x 10 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography and eluted with DCM / MeOH (20:1) to give 3-(6-(2-(7-(5-(3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)pyridin-2-yl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-oxoethyl)-1-oxo-3.5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (118 mg, 55%). LCMS (ES, m / z): 899.55 [M+H].+ .
[0384] Step 6: Preparation of 3-(6-(2-(7-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-oxoethyl)-1-oxo-3.5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (Compound 70):
[0385] To a solution of 3-(6-(2-(7-(5-(3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)pyridin-2-yl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-oxoethyl)-1-oxo-3.5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (118 mg, 0.13 mmol) in DCM (1 mL) was added TFA (0.5 mL), and the mixture was stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure. The crude product (90 mg) was purified by Prep-HPLC using the following conditions (column: Xselect CSH C18 OBD column 30x150 mm 5 μm, n; mobile phase A: water (0.1% TFA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 11% B to 41% B in 7 minutes; wavelength: 254nm; RT1 (min): 5.89) to give 3-(6-(2-(7-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-oxoethyl)-1-oxo-3.5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)piperidine-2,6-dione (27 mg, 25%) as a white solid. LCMS (ES, m / z): 815.4 [M+H]+; 1H NMR(400MHz,DMSO-d6)δ(ppm):12.45(s,1H),10.98(s,1H),8.32-8.22(m,2H),8.02-7.62 (m,4H),7.55-7.48(m,1H),7.36-7.27(m,1H),6.99-6.94(m,1H),4.48-4.42(m,1H),4.40- 4.20(m,2H),3.99-3.80(m,4H),3.72-3.58(s,6H),3.46-3.18(m,2H),3.28(s,2H),2.45- 2.36(m,1H),2.05-1.94(m,1H),1.86-1.73(m,4H),1.76-1.56(m,4H),1.25-1.05(m,12H).
[0386] According to the synthetic route of compound 70, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are shown in Example 7 above, but the molar masses of the starting compounds and intermediates were kept unchanged):
[0387] Example 8: Preparation of 1-(3-(4-(1-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-methylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)dione (Compound 75):
[0388] Step 1: Preparation of 3-(3-bromophenyl)aminopropionic acid:
[0389] An aqueous solution of m-bromoaniline (3 g, 17.439 mmol) was treated with acrylic acid (3.77 g, 52.317 mmol) at 70°C under a nitrogen atmosphere for 3 h. Ethanol (6 mL) was added when the mixture was cooled to 5°C. The resulting mixture was stirred at room temperature for 12 h. The resulting mixture was concentrated under vacuum. The residue was dissolved in dichloromethane. The residue was purified by silica gel column chromatography and eluted with PE / EA to give 3-(3-bromophenyl)aminopropionic acid (4 g, 94%) as an oily liquid. LCMS (ES, m / z): 244 [M+H] + .
[0390] Step 2: Preparation of 1-(3-bromophenyl)dihydropyrimidine-2,4(1H,3H)-dione:
[0391] A solution / mixture of 3-((3-bromophenyl)amino)propionic acid (4 g, 16.388 mmol, 1 eq) and urea (1.97 g, 32.776 mmol, 2 eq) was boiled overnight in 20 ml of acetic acid. 10% HCl was added to the above mixture until pH = 1, and the resulting mixture was boiled for 30 minutes. The mixture was allowed to cool to room temperature. The reaction was quenched with water. The precipitated solid was collected by filtration and washed with water to give 1-(3-bromophenyl)dihydropyrimidine-2,4-dione (2.55 g, 58%) as a white solid. LCMS (ES, m / z): 269 [M+H] + .
[0392] Step 3: Preparation of 1-(3-(4-(1-(5-(3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-methylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)dione (Compound 75):
[0393] To a solution of 3-fluoro-5-((6-(4-(piperazine-1-methyl)piperidin-1-yl)pyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)-1H-indazole (100 mg, 0.183 mmol) and 1-(3-bromophenyl)dihydropyrimidine-2,4-(1H,3H)dione in dioxane (2 mL) was added the third generation t-BuXPhos precatalyst (14.55 mg, 0.018 mmol), t-BuXPhos (15.53 mg, 0.037 mmol) and Cs2CO3 (178.78 mg, 0.549 mmol) and stirred overnight at 90°C under a nitrogen atmosphere. The mixture was allowed to cool to room temperature. The reaction was quenched with water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The crude product (100 mg) was purified by Prep-HPLC using the following conditions (column: SunFire Prep C18 OBD column, 19*150 mm, 5 μm; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 30% B to 50% B in 7.2 min; wavelength: 254 / 210 nm; RT1 (min): 8) to give 1-(3-(4-(1-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-methylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)dione (Compound 75) (4.0 mg, 2.88%) as a white solid. LCMS (ES, m / z):735[M+H]+; 1H NMR (400MHz, DMSO-d6) δ (ppm): 10.50 (s, 1H), 8.37 (s, 1H), 8.01 (s, 1H), 7.86-7.84 (d, J = 8.0Hz ,1H),7.73(s,1H),7.64(s,1H),7.59-7.57(d,J=8.0Hz,2H),7.38-7.31(m,3H),7.76-7.74(d, J=8.0Hz,1H),2.25-4.22(d,J=12.0Hz,2H),3.91-3.88(t,2H),2.79-2.79(m,8H),2.34-2.26( m,6H),2.18-2.11(m,4H),1.76-1.73(m,3H),1.24-1.19(d,J=20.0Hz,12H),1.13-1.08(m,2H).
[0394] According to the synthetic route of compound 75, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are shown in Example 8 above, but the molar masses of the starting compounds and intermediates were kept unchanged):
[0395] Example 9: Preparation of 3-((2-fluoro-5-(4-((1-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione (Compound 83):
[0396] Step 1: Preparation of 3-((5-bromo-2-fluorophenyl)amino)piperidine-2,6-dione:
[0397] 5-Bromo-2-fluoroaniline (1 g, 5.3 mmol), 3-bromo-2,6-dione (3.03 g, 15.8 mmol), silver trifluoromethanesulfonate (0.27 g, 1.05 mmol) and sodium hydroxide (1.33 g, 15.8 mmol) were stirred at 80 ° C under a nitrogen atmosphere for 7 days. The reaction was quenched with water at room temperature. The resulting mixture was extracted with EtOAc (3x50 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was solidified with Et2O (3×10 mL). 3 ((4-bromo-2-fluorophenyl) amino) piperidine-2.6-dione (200 mg, 12.62%) was obtained as an off-white solid. LCMS (ES, m / z): 301 [M+H] + .
[0398] Step 2: Preparation of 3-((2-fluoro-5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione (Compound 83):
[0399] To a solution of 3-fluoro-5-((6-(4-(piperazin-1-ylmethyl)piperidin-1-yl)pyridin)-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1H-indazole (100 mg, 0.18 mmol) in 1,4-dioxane (2 mL) were added a solution of 3-((4-bromo-2-fluorophenyl)amino)piperidine-2,6-dione (110 mg, 0.37 mmol), t-BuXPhos (16 mg, 0.04mmol), di-tert-butyl[2',4',6'-tri(propane-2-yl)-[1,1'-biphenyl][1,1'-biphenyl]-2-yl]phosphine; Chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (29mg, 0.04mmol) and Cs2CO3 (179mg, 0.55mmol) were stirred at 90°C under a nitrogen atmosphere overnight. The reaction was quenched with water at room temperature. The resulting mixture was extracted with ethyl acetate (3x20mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to obtain a crude product which was purified by Prep-HPLC using the following conditions (column: Welch Ultimate HS-C18, 21.2*250 mm, 7 μm; mobile phase A: water (0.05% The reaction mixture was stirred for 2 h at 4 °C for 1 h (10 min) at 4 °C for 3 h. The mixture was stirred for 2 h at 4 °C for 3 h. The resulting mixture was stirred for 2 h. The resulting mixture was stirred for 3 h. The mixture was stirred for 2 h. The resulting mixture was stirred for 3 h. The mixture was stirred for 2 h. The resulting mixture was stirred for 3 h. The mixture was stirred for 2 h. The resulting mixture was stirred for 3 h. The mixture was stirred for 2 h. The resulting mixture was stirred for 3 h. The mixture was stirred for 3 h. The resulting mixture was stirred for 2 h. +;1H NMR(400MHz,DMSO-d6)δ10.86(s,1H),8.79(s,1H),7.61(d,J=1.2Hz,1H),7.56(s,1H),7.42-7.39(m,1H),7 .29-7.27(m,2H),7.08-7.06(d,J=8.0Hz,2H),6.99-6.98(m,1H),6.97-6.91(m,2H),5.90(s,1H),4.52(s,1H ),3.69-3.66(d,J=12.0Hz,5H),3.23(s,4H),2.79-2.70(m,1H),2.66-2.56(m,4H),2.35(s,1H),2.23(s,2H ),2.17(s,2H),2.11(m,2H),1.82-1.79(d,J=11.6Hz,3H),1.28-1.20(m,2H),1.17-1.13(d,J=15.2Hz,12H).
[0400] According to the synthetic route of compound 83, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are shown in Example 9 above, but the molar masses of the starting compounds and intermediates were kept unchanged):
[0401] Example 10: Preparation of 1-(6-(1-(2-(4-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 92):
[0402] Step 1: Preparation of tert-butyl 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indolazol-6-yl)piperidin-1-yl)acetic acid ethyl ester:
[0403] Tert-butyl bromoacetate (1.08 g, 5.5 mmol) and DIEA (3.23 g, 25 mmol) were added to a stirred MeCN (30 mL) solution of 1-(1-methyl-6-(piperidin-4-yl)-1H-indol-3-yl)dihydropyrimidine-2,4(1H, 3H)-diketone hydrochloride (1.80 g, 5 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water at room temperature. The resulting mixture was extracted with DCM (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography and eluted with DCM / MeOH (20:1) to afford tert-butyl 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indolazol-6-yl)piperidin-1-yl)acetate (1.65 g, 75%) as a yellow oil, which was used directly in the next reaction. LCMS (ES, m / z): 442.2 [M+H] + .
[0404] Step 2: Preparation of 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)yl)-1-methyl-1H-indolazol-6-yl)piperidin-1-yl)acetic acid:
[0405] To a solution of tert-butyl 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indol-6-yl)piperidin-1-yl)acetic acid ethyl ester (1.65 g, 3.74 mmol) in DCM (10 mL) was added TFA (10 mL) and stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure, dissolved in DCM (50 mL), washed with H₂O (50 mL), and separated. The aqueous phase was extracted with DCM (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to yield 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indol-6-yl)piperidin-1-yl)acetic acid (1.15 g, 80%) as a yellow oil. The crude product was used directly in the next step without further purification. LCMS (ES, m / z): 384 [M+H]-.
[0406] Step 3: Preparation of 1-(6-(1-(2-(4-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)dione:
[0407] To a solution of 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)yl)-1-methyl-1H-indol-6-yl)piperidin-1-yl)acetic acid (100 mg, 0.26 mmol) in DMA (2 mL) was added 3-fluoro-5-((6-(piperazin-1-yl)pyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole (124 mg, 0.26 mmol), HATU (148 mg, 0.39 mmol), and DIEA (67 mg, 0.52 mmol). The resulting mixture was stirred at room temperature under nitrogen overnight. The reaction was quenched with water (20 mL) and extracted with EA (4 x 10 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography and eluted with DCM / MeOH (20:1) to give 1-(6-(1-(2-(4-(5-(3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)dione (108 mg, 50%). LCMS (ES, m / z): 901.4 [M+H]. + .
[0408] Step 4: Preparation of 1-(6-(1-(2-(4-(5-(3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 92):
[0409] To a solution of 1-(6-(1-(2-(4-(5-(3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)dione (108 mg, 0.12 mmol) in DCM (1 mL) was added TFA (0.5 mL), and the mixture was stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC using the following conditions (column: Xselect CSH C18 OBD column 30x150mm 5μm, n; mobile phase A: water (0.1% TFA), mobile phase B: ACN; flow rate: 60mL / min; gradient: 11% B to 41% B in 7 minutes; wavelength: 254nm; RT1 (min): 5.89) to give 1-(6-(1-(2-(4-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 92) (18 mg, 22%) as a white solid. LCMS (ES, m / z):817.4[M+H]+; 1H NMR(400MHz,DMSO-d6)δ(ppm):12.48(s,1H),10.68(s,1H),8.32-8.15(m, 2H),8.02-7.52(m,5H),7.36-7.27(m,1H),6.59-6.54(m,1H),3.96(s,3H), 3.85-3.52(m,10H),3.28(s,2H),2.75-2.68(m,3H),2.55-2.50(m,2H),2. 45-2.36(m,2H),2.05-1.94(m,4H),1.76-1.58(m,4H),1.23-1.08(m,12H).
[0410] Example 11: Preparation of 1-(6-(3,3-difluoro-1-(2-(4-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 93):
[0411] Step 1: Preparation of tert-butyl 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indol-6-yl)-3,3-difluoropiperidin-1-yl)acetate:
[0412] Tert-butyl bromoacetate (1.08 g, 5.5 mmol) and DIEA (3.23 g, 25 mmol) were added to a stirred MeCN (30 mL) solution of 1-(6-(3,3-difluoropiperidin-4-yl)-1-methyl-1H-indol-3-yl)dihydropyrimidine-2,4(1H, 3H)-dion hydrochloride (1.80 g, 5 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water at room temperature. The resulting mixture was extracted with DCM (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography and eluted with DCM / MeOH (20:1) to afford tert-butyl 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indol-6-yl)-3,3-difluoropiperidin-1-yl)acetate (1.65 g, 75%) as a yellow oil, which was used directly in the next reaction. LCMS (ES, m / z): 478.2 [M+H] + .
[0413] Step 2: Preparation of 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indol-6-yl)-3,3-difluoropiperidin-1-yl)acetic acid:
[0414] To a solution of tert-butyl 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indol-6-yl)-3,3-difluoropiperidin-1-yl)acetate (1.65 g, 3.74 mmol) in DCM (10 mL) was added TFA (10 mL) and stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure, dissolved in DCM (50 mL), washed with H₂O (50 mL), and separated. The aqueous phase was extracted with DCM (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to yield 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indol-6-yl)-3,3-difluoropiperidin-1-yl)acetic acid (1.15 g, 80%) as a yellow oil. The crude product was used directly in the next step without further purification. LCMS (ES, m / z): 422 [M+H] - .
[0415] Step 3: Preparation of 1-(6-(3,3-difluoro-1-(2-(4-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione:
[0416] To a solution of 2-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)yl)-1-methyl-1H-indol-6-yl)-3,3-difluoropiperidin-1-yl)acetic acid (100 mg, 0.26 mmol) in DMA (2 mL) was added 3-fluoro-5-((6-(piperazin-1-yl)pyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole (124 mg, 0.26 mmol), HATU (148 mg, 0.39 mmol), and DIEA (67 mg, 0.52 mmol). The resulting mixture was stirred at room temperature under nitrogen overnight. The reaction was quenched with water (20 mL) and extracted with EA (4 x 10 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography and eluted with DCM / MeOH (20:1) to give 1-(6-(3,3-difluoro-1-(2-(4-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (108 mg, 50%). LCMS (ES, m / z): 937.4 [M+H] + .
[0417] Step 4: Preparation of 1-(6-(3,3-difluoro-1-(2-(4-(5-(3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 93):
[0418] To a solution of 1-(6-(3,3-difluoro-1-(2-(4-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (108 mg, 0.12 mmol) in DCM (1 mL) was added TFA (0.5 mL), and the mixture was stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC using the following conditions (column: Xselect CSH C18 OBD column 30x150mm 5μm, n; mobile phase A: water (0.1% TFA), mobile phase B: ACN; flow rate: 60mL / min; gradient: 11% B to 41% B in 7 minutes; wavelength: 254nm; RT1 (min): 5.89) to give 1-(6-(3,3-difluoro-1-(2-(4-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 93) (18 mg, 22%) as a white solid. LCMS (ES, m / z):853.4[M+H]+; 1H NMR(400MHz,DMSO-d6)δ(ppm):12.44(s,1H),10.66(s,1H),8.35-8.17(m,2H), 8.05-7.52(m,5H),7.38-7.28(m,1H),6.59-6.55(m,1H),4.22-4.16(m,1H),3.9 6(s,3H),3.85-3.52(m,10H),3.28(s,2H),2.75-2.68(m,2H),2.56-2.50(m,2H ),2.46-2.38(m,2H),2.05-1.95(m,4H),1.80-1.58(m,2H),1.24-1.08(m,12H).
[0419] According to the synthetic route of compound 93, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are as described in Example 11 above, but the molar masses of the starting compounds and intermediates were kept unchanged):
[0420] Example 12: Preparation of 1-(8-(4-((1-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-methylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 96):
[0421] Step 1: Preparation of tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)imidazo[1,2-a]pyridin-8-yl)piperazine-1-carboxylate:
[0422] To a solution of 1-(8-bromoimidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (300 mg, 0.6 mmol) in THF (5 mL) were added tert-butylpiperazine-1-carboxylate (450 mg, 1.8 mmol), RuPhos Palladacycle G3 (104 mg, 0.12 mmol), RuPhos (58 mg, 0.12 mmol) and t-BuONa (179 mg, 1.8 mmol), and the resulting mixture was stirred at 85 ° C overnight under a nitrogen atmosphere. The reaction was quenched with water at room temperature. The resulting mixture was extracted with EA (3x20 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative thin-layer chromatography (DCM / MeOH 10:1) to give tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)imidazo[1,2-a]pyridin-8-yl)piperazine-1-carboxylate (200 mg, 46.81%) as a yellow oil. LCMS (ESI): m / z 415 [M+1] + .
[0423] Step 2: Preparation of 1-(8-(piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione:
[0424] To a solution of tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)imidazo[1,2-a]pyridin-8-yl)piperazine-1-carboxylate (180 mg, 0.3 mmol) in DCM (8 mL) was added TFA (2 mL) and the mixture was stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure. 1-(8-(piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (110 mg, 83.46%) was obtained as a yellow oil. The crude product was used directly in the next step without further purification. LCMS (ESI): m / z 315 [M+1] + .
[0425] Step 3: Preparation of 1-(8-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione:
[0426] To a stirred solution of 1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidine-4-carbaldehyde (134.5 mmol, 0.24 mmol) in DMA (1 mL) was added 1-(8-(piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (88 mmol, 0.24 mmol) STAB (106 mg, 0.5 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water at room temperature. The resulting mixture was extracted with DCM (3 x 10 mL). The combined organic layers were washed with water (3 x 5 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. 1-(8-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (131 mg, 60%) was obtained as a yellow oily liquid. LCMS (ESI): m / z 859.4 [M+1] + .
[0427] Step 4: Preparation of 1-(8-(4-((1-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 96):
[0428] To a solution of 1-(8-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (130 mg, 0.14 mmol) in DCM (1 mL) was added TFA (0.5 mL), and the mixture was stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure. The crude product (90 mg) was purified by Prep-HPLC using the following conditions (column: Xselect CSH C18 OBD column 30x150 mm 5 μm, n; mobile phase A: water (0.1% TFA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 11% B to 41% B in 7 minutes; wavelength: 254 nm; RT1 (min): 5.89) to give 1-(8-(4-((1-(5-((3-fluoro-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-methylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (Compound 96) (35.4 mg, 30%) as a white solid. LCMS (ESI): m / z 775.4 [M+1] +;1H NMR(400MHz,DMSO-d6)δ (ppm):12.55(s,1H),10.96(s,1H),9.37(s,1H),7.64-7.58(d,J=8.4Hz,1H),7.52-7.42(m,2H),7.26-7.22( m,1H),7.18-7.11(m,2H),6.99-6.96(d,J=13.2Hz,1H),5.45(s,1H),5.11-5.01(m,1H),4.41-4.18(m,2H),3 .98-3.81(m,4H),3.72-3.58(s,6H),3.45-3.17(m,3H),2.95-2.88(m,1H),2.69-2.52(m,2H),2.44-2.36(m, 1H),2.22(s,2H),2.15(s,1H),2.01-1.94(m,1H),1.84-1.73(m,4H),1.75-1.56(m,4H),1.22-1.04(m,12H).
[0429] According to the synthetic route of compound 96, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are as described in Example 12 above, but the molar masses of the starting compounds and intermediates were kept unchanged):
[0430] Example 13: Preparation of 3-(4-(1-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Compound 99):
[0431] Step 1: Preparation of tert-butyl 4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate:
[0432] To a solution of 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (1.25 g, 3.70 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (2.31 g, 7.40 mmol) in 1,4-dioxane (20 mL) was added cesium fluoride (1.14 g, 7.40 mmol) and Pd(dppf)Cl2 (540 mg, 740 μmol) under nitrogen atmosphere and the mixture was stirred at 85° C. for 3 hours. The mixture was cooled to room temperature, diluted with ethyl acetate (50 mL) and filtered through celite / silica gel. After washing with ethyl acetate (20 mL), the filtrate was washed with water and the separated liquids were combined. The organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography (EA:PE = 10:1) to obtain tert-butyl 4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate (980 mg, 60% yield). LCMS (ESI) m / z: 441.2 (M+H) + .
[0433] Step 2: Preparation of tert-butyl 4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)piperidine-1-carboxylate:
[0434] To a solution of 4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate (980 mg, 2.22 mmol) in methanol (20 mL) was added palladium (10% on carbon, 0.95 g, 0.89 mmol), and the mixture was stirred at room temperature under a hydrogen balloon for 24 hours. The reaction mixture was filtered through celite and washed with a mixture of dichloromethane (20 mL×3). The combined washings were concentrated under reduced pressure to give tert-butyl 4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)piperidine-1-carboxylate (930 mg, yield 94%). LCMS (ESI) m / z: 443.2 (M+H)+.
[0435] Step 3: Preparation of 3-(3-methyl-2-oxo-4-(piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione hydrochloride:
[0436] Tert-butyl 4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)piperidine-1-carboxylate (930 mg, 2.09 mmol) and hydrochloric acid (4M, 2.5 mL) were stirred in ethyl acetate (10 mL) overnight. The resulting mixture was concentrated under reduced pressure. The residue was washed with ethyl acetate (5x20 mL) and slurried. 3-(3-methyl-2-oxo-4-(piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione hydrochloride (610 mg, 85% yield) was obtained. LCMS(ESI)m / z:343.2(M+H)+.
[0437] Step 4: Preparation of 3-(4-(1-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione:
[0438] To a stirred solution of 1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)piperidine-4-carbaldehyde (100 mg, 0.2 mmol) in DCE (2 mL) was added 3-(3-methyl-2-oxo-4-(piperidin-4-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione hydrochloride (69 mg, 0.2 mmol) and treated with NaOAc (82.4 mg, 1 mmol) at room temperature for 2 hours. STAB (76 mg, 0.4 mmol) was added at room temperature. The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was quenched with water. The resulting mixture was extracted with DCM (3x10 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. 3-(4-(1-(1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (108 mg, 61%) was purified as butter by pre-thin layer chromatography (PE / EA 1:1). LCMS (ESI) m / z: 887.5 (M+H) + .
[0439] Step 5: Preparation of 3-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Compound 99):
[0440] In a 50 mL round-bottom flask was added 3-(4-(1-(1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (108 mg, 0.12 mmol), DCM (8 mL) and TFA (2 mL). The resulting mixture was stirred at room temperature under nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure to give the crude product which was purified by Prep-HPLC using the following conditions (column: Xselect CSH C18 OBD column 30*150 mm 5 μm, n; mobile phase A: water (0.05% The mixture was stirred for 2 h at 4 ℃ for 1 h (10 min) and 30 min (15 min) to obtain 3-(4-(1-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Compound 99) (44 mg, 27%) as a white solid. LCMS (ESI) m / z: 803.3 (M+H)+; 1H NMR(400MHz,DMSO-d6)δ(ppm):12.52(s,1H),10.96(s,1H),9.46(s,1H),7.98-7.58 (m,3H),7.50-7.44(m,2H),7.26-7.16(m,3H),7.03-6.99(d,J=6.8Hz,1H),5.10-5.0 5(m,1H),4.39-4.34(d,J=17.2Hz,2H),4.28-4.24(m,1H),4.034-4.00(d,J=10.0Hz, 3H),3.86(s,3H),3.65-3.63(d,J=8.4Hz,2H),3.24-3.12(m,5H),2.95-2.88(m,3H), 2.68-2.62(m,2H),2.41-2.34(m,1H),2.25(s,2H),2.16(s,2H),1.96-1.94(m,1H),1.86-1.83(d,J=12.3Hz,2H),1.22-1.10(m,12H).
[0441] Example 14: Preparation of 3-(4-(3-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)oxy)propyl-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Compound 100):
[0442] Step 1: Preparation of 3-fluoro-5-((6-(4-(propyl-2-yn-1-yloxy)piperidin-1-yl)pyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole:
[0443] To a stirred solution of 4-(prop-2-yn-1-yloxy)piperidine (780 mg, 5.60 mmol) and 3-fluoro-5-((6-fluoropyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)-1-(tetrahydro-2H-pyran-4yl)-1H-indazole (1.19 g, 2.55 mmol) in DMSO was added dropwise DIEA (1.65 g, 12.74 mmol) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 120 ° C under a nitrogen atmosphere. The reaction was quenched with water at room temperature. The resulting mixture was extracted with EtOAc (3x50 mL). The combined organic layers were washed with water (4x5 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / electroEA (1:1) to give 3-fluoro-5-((6-(4-(propyl-2-yn-1-yloxy)piperidin-1-yl)pyridin-3-yl}(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole (400 mg, 26.76%) as a yellow oily liquid. LCMS (ESI) m / z: 587.3 (M+H) + .
[0444] Step 2: Preparation of 3-(4-(3-(1-(5-(3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)oxy)prop-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione:
[0445] 3-(4-Bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (150 mg, 0.44 mmol), 3-fluoro-5-((6-(4-(propyl-2-yn-1-yloxy)piperidin-1-yl)pyridin-3-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-indazole (390 mg, 0.67 mmol), Pd(PPh3)4 (103 mg, 0.09 mmol), and 2-methylpropane-2-amine (97 mg, 1.33 mmol) were added to 1,4-dioxane (4 mL), and the mixture was stirred at 80°C under a nitrogen atmosphere overnight. The reaction was quenched with water at room temperature. The resulting mixture was extracted with ethyl acetate (3x20 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by pre-thin layer chromatography (DCM / MeOH 10:1) to give 3-(4-(3-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)oxy)prop-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (150 mg, 40.07%) as a yellow oily liquid. LCMS (ESI) m / z: 844.4 (M+H) + .
[0446] Step 3: Preparation of 3-(4-(3-(1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)oxy)propyl-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Compound 100):
[0447] To a solution of 3-(4-(3-(1-(5-(3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)oxy)prop-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (150 mg, 0.18 mmol) in DCM (6 mL) was added TFA (1.5 mL) and stirred at room temperature under nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC using the following conditions (column: XselectCSH Prep Fluoro-Phenyl OBD C18 column, 30*150 mm, 5 μm; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 60 mL / min mL / min; gradient: 28% B to 43% B at 8 minutes; wavelength: 254 nm / 220 nm; RT1 (min): 6.68 to give 3-(4-(3-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)oxy)propyl-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Compound 100) (52.7 mg, 37.97%) as a white solid. LCMS (ESI) m / z: 760.3 (M+H) + ;1H NMR (400MHz, DMSO-d6) δ12.57(s,1H),11.14(s,1H),7.90(d,J=2.0Hz,1H),7.60-7.55(m,2H),7.4 6-7.43(m,1H),7.26-7.24(m,1H),7.19-7.11(m,3H),7.05-7.01(m,1H),5.43-5.38(m,1H),4.54( s,2H),3.90-3.84(m,3H),3.65(s,3H),3.37-3.35(m,2H),2.95-2.82(m,1H),2.73-2.60(m,2H),2 .23-2.15(d,J=32.4Hz,4H),2.04-2.01(m,3H),1.59-1.57(s,2H),1.18-1.13(d,J=22.4Hz,12H).
[0448] According to the synthetic route of compound 100, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are referred to the above Example 14, but the molar masses of the starting compounds and intermediates were controlled to remain unchanged):
[0449] Example 15: Preparation of (R)-3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 132) and (S)-3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 133)
[0450] Step 1: 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 36) (50 mg) CHIRAL-HPLC: Column: JW-CHIRAL ART Cellulose-SB, 4.6*100 mm; 3 μm; Mobile phase A: Hex (0.1A): (IPA:DCM=1:2)=50:50; Flow rate: 1 mL / min; Gradient: 0% B to 0% B; Injection volume: 5 μl M1 was used to prepare (S)-3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 133) (6.0 mg) as a white solid. LCMS (ES, m / z): 774.9 [M+H] +Chiral high performance liquid chromatography: Rt = 3.423; and (R)-3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 132) (5.6 mg) as a white solid. LCMS (ES, m / z): 774.9 [M+H] + ; Chiral HPLC: Rt=4.619.
[0451] Example 16: Synthesis of 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-(2-fluoro-N-(2,6-dioxo-dihydropyrimidine-2,4(1H,3H))-benzamide (Compound 122):
[0452] Step 1: Preparation of 3-(5-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl](2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-(2-fluoro-N-(2,6-dioxo-dihydropyrimidine-2,4(1H,3H))-benzamide:
[0453] To a stirred solution of 1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidine-4-carboxaldehyde (100 mg, 0.2 mmol) in DCE (2 mL) was added 2-(2,6-dioxopiperidin-3-yl)-2-fluoro-4-(piperazin-1-yl)benzamide hydrochloride solution (70 mg, 0.2 mmol) and STAB (76 mg, 0.4 mmol) was added at room temperature. The resulting mixture was stirred overnight under a nitrogen atmosphere at room temperature. The reaction was quenched with water. The resulting mixture was extracted with DCM (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. 3-(5-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl](2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-(2-fluoro-N-(2,6-dioxo-dihydropyrimidine-2,4(1H,3H))-benzamide (100 mg, 64.22%) was purified by pre-TLC (PE / EA 1:1) as a yellow oil. LCMS (ES, m / z): 879 [M+H] + .
[0454] Step 2: Preparation of 3-(5-(4-((1-(5-((3-fluoro-1H-indol-5-yl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-(2-fluoro-N-(2,6-dioxo-dihydropyrimidine-2,4(1H,3H))-benzamide (Compound 122):
[0455] A 50 mL round-bottom flask was charged with 3-(5-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-yl](2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-(2-fluoro-N-(2,6-dioxo-dihydropyrimidine-2,4(1H,3H))-benzamide (120 mg, 0.14 mmol), DCM (8 mL) and TFA (2 mL). The resulting mixture was stirred at room temperature under a nitrogen atmosphere overnight. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC using the following conditions (column: Xselect CSH C18 OBD column 30*150mm 5μm, n; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 60mL / min; gradient: 16% B to 36% B in 7 minutes, 36% B; wavelength: 254nm; RT1 (minute): 5.68; number of operations: 0) to obtain 3-(5-(4-((1-(5-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)- 1H-indol-5-yl](2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylmethylene)methyl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-(2-fluoro-N-(2,6-dioxo-dihydropyrimidine-2,4(1H,3H))-benzamide (74.1 mg, 67.79%) as a white solid. LCMS (ES, m / z): 789 [M+H]+; 1H NMR (400MHz, DMSO-d6) δ (ppm): 12.58 (s, 1H), 10.99 (s, 1H), 9.49 (s, 1H), 7.97-7.96 (d, J = 2.4Hz, 1H), 7.61-7.60 (d, J = 8.4Hz, 1 H),7.53-7.44(m,3H),7.26-7.16(m,3H),7.00-6.99(d,J=6.8Hz,1H),5.10-5.05(m,1H),4.39-4.34(d,J=17.2Hz,2H),4.28-4 .22(m,3H),4.03-4.00(d,J=10.0Hz,3H),3.65-3.63(d,J=8.4Hz,2H),3.24-3.12(m,5H),2.95-2.88(m,3H),2.62-2.58(d,J=1 6.4Hz,1H),2.41-2.34(m,1H),2.24(s,2H),2.16(s,2H),1.97-1.93(m,1H),1.86-1.84(d,J=12.3Hz,2H),1.23-1.13(m,12H).
[0456] According to the synthetic route of compound 122, the following compounds were synthesized using the following starting compounds or intermediates (the synthetic steps are as described in Example 16 above, but the molar masses of the starting compounds and intermediates were kept unchanged):
[0457] The compounds of this application and related NMR data are shown in the following table:
[0458] Biological evaluation:
[0459] The present application is further described below in conjunction with test examples, but these example tests are not intended to limit the scope of the present application.
[0460] Test Example 1 Degradation activity of the disclosed compounds on ERα in MCF7 cells
[0461] ERα-positive human breast cancer cells MCF-7 (ATCC, HTB-22) were cultured in EMEM medium (ATCC, Catalog No. 30-2003) containing 10% fetal bovine serum (Thermo Fisher Scientific, Catalog No. 10099141) and 10 μg / mL bovine insulin at 37°C in 95% air and 5% CO2 at 25 cm 2 or 75cm 2 Subculture 2 to 3 times a week in plastic tissue culture flasks.
[0462] The cells were plated at 1×10 6Cells were seeded at a density of 1.8 mL / well in a 6-well cell culture plate and incubated at 37°C in 95% air and 5% CO2. Test compounds were added 24 hours later: starting at 10 mM (dissolved in DMSO), the compound was serially diluted 10-fold with DMSO to prepare a gradient stock solution. Complete culture medium containing 1% DMSO was prepared for further dilutions, temporarily referred to as "dilution buffer." Working solutions were prepared by diluting each stock solution with 99 volumes of dilution buffer: 1 μL of the 10 mM stock solution was added to 99 μL of dilution buffer, mixed thoroughly, and finally 10 μL of the working solution was added to the plate seeded with cells. The final DMSO concentration in the cell culture medium was 0.2%, and the final concentration of the test compound ranged from 1 nM to 100 nM. The cells were incubated at 37°C for 6 hours.
[0463] Aspirate the culture medium, wash twice with pre-cooled PBS, add 1 mL of PBS to each well, collect the cells into an EP tube using a cell scraper, centrifuge at 4°C, 4000 rpm for 5 minutes, and aspirate the PBS. TM Total protein was extracted using animal cell / tissue total protein extraction reagent. Protein concentration was determined by the BCA assay. 30 μg of protein was mixed with 5× SDS-PAGE loading buffer, boiled for 10 minutes, and then added to the wells of a precast gel comb. The sample was run at a constant voltage of 80 V for 30 minutes. After the sample entered the separating gel, the sample was run at 120 V. A Bio-Rad Transblot "sandwich" was assembled: sponge-filter paper-gel-membrane-filter paper-sponge. Transfer was performed at 4°C at 0.3 amp for 1 hour. Blocking was performed with 5% nonfat dry milk for 1 hour at room temperature. Estrogen Receptor alpha Antibody (Thermo Fisher Scientific, Cat. No. MA5-14104) was then added with gentle shaking at 4°C overnight. Nonspecifically bound antibodies were removed from the membrane using TBST. A goat anti-mouse IgG-HRP secondary antibody was added and incubated at room temperature for 1 hour. ECL staining was performed. Protein degradation levels were calculated using grayscale.
[0464] Figure 1A illustrates the ERα degradation activity of exemplary compounds 1, 2, 5, 6, 7, and 13 of the present disclosure in the MCF-7 cell line after 6 hours of administration. Figure 1B illustrates the ERα degradation activity of exemplary compounds 27, 30, 31, 34, 35, and 37 of the present disclosure in the MCF-7 cell line after 6 hours of administration. Figure 1C illustrates the ERα degradation activity of exemplary compounds 44, 46, 47, 48, 57, and 59 of the present disclosure in the MCF-7 cell line after 6 hours of administration. Figure 1D illustrates the ERα degradation activity of exemplary compounds 61, 66, 76, 88, 89, and 90 of the present disclosure in the MCF-7 cell line after 6 hours of administration. Figure 1E illustrates the ERα degradation activity of exemplary compounds 103, 104, 110, 119, 120, and 121 of the present disclosure in the MCF-7 cell line after 6 hours of administration.
[0465] The DC50 values (i.e., the concentration of the test compound that degrades 50% of the target protein) for various compounds of the present disclosure were calculated and are shown in Table 1 below. A corresponds to a DC50 value below 10 nM. B corresponds to a DC50 value greater than 10 nM and less than 100 nM; and C corresponds to a DC50 value greater than 100 nM.
[0466] Table 1. DC50 values in MCF-7 cell line.
[0467] Test Example 2 Time-dependent activity of the disclosed compounds on ERα degradation in MCF7 cells
[0468] ERα-positive human breast cancer cells MCF-7 (ATCC, HTB-22) were cultured in EMEM medium (ATCC, Catalog No. 30-2003) containing 10% fetal bovine serum (Thermo Fisher Scientific, Catalog No. 10099141) and 10 μg / mL bovine insulin at 37°C in 95% air and 5% CO2 at 25 cm 2 or 75cm 2 Subculture 2 to 3 times a week in plastic tissue culture flasks.
[0469] The cells were plated at 1×10 6Cells were seeded at a density of 1.8 mL / well in a 6-well cell culture plate and incubated at 37°C in 95% air and 5% CO2. Test compounds were added 24 hours later: starting at 10 mM (dissolved in DMSO), the compound was serially diluted 10-fold in DMSO to prepare a gradient stock solution. Complete culture medium containing 1% DMSO was prepared for further dilutions, temporarily referred to as "dilution buffer." Working solutions were prepared by diluting each stock solution with 99 volumes of dilution buffer: 1 μL of the 10 μM stock solution was added to 99 μL of dilution buffer, mixed, and finally 10 μL of the working solution was added to the plate seeded with cells. The final DMSO concentration in the cell culture medium was 0.2%, and the final concentration of the test compound was 10 nM. The cells were incubated at 37°C for 0.5, 1, 2, 4, 6, and 24 hours.
[0470] Aspirate the culture medium, wash once with pre-cooled PBS, add 1 mL of PBS to each well, collect the cells into an EP tube with a cell scraper, centrifuge at 4°C, 4000 rpm for 5 minutes, and aspirate the PBS. TM Total protein was extracted using animal cell / tissue total protein extraction reagent. Protein concentration was determined by the BCA assay. 30 μg of protein was mixed with 5× SDS-PAGE loading buffer, boiled for 10 minutes, and then added to the wells of a precast gel comb. The sample was run at a constant voltage of 80 V for 30 minutes. After the sample entered the separating gel, the sample was run at 120 V. A Bio-Rad Transblot "sandwich" was assembled: sponge-filter paper-gel-membrane-filter paper-sponge. Transfer was performed at 4°C at 0.3 amp for 1 hour. Blocking was performed with 5% nonfat dry milk for 1 hour at room temperature. Estrogen Receptor alpha Antibody (Thermo Fisher Scientific, Cat. No. MA5-14104) was then added with gentle shaking at 4°C overnight. Nonspecifically bound antibodies were removed from the membrane using TBST. A goat anti-mouse IgG-HRP secondary antibody was added and incubated at room temperature for 1 hour. ECL staining was performed. Protein degradation levels were calculated using grayscale.
[0471] 2A to 2D illustrate the time-dependent activity of ERα degradation in MCF-7 cell lines upon administration of 10 nM of exemplary compounds 5, 31, 47, and 48 of the present disclosure.
[0472] Test Example 3 Inhibitory effect of the compound of the present application on MCF-7 cell proliferation
[0473] Human breast cancer cells MCF-7 (ATCC, HTB-22) were cultured in EMEM medium (ATCC, Catalog No. 30-2003) containing 10% fetal bovine serum (Thermo Fisher Scientific, Catalog No. 10099141) and 10 μg / mL bovine insulin at 37°C in 95% air and 5% CO2 at 25 cm2 or 75cm 2 Subculture 2 to 3 times a week in plastic tissue culture flasks.
[0474] The cells were plated at 3 × 10 3 Cells were seeded at a density of 90 μL / well in a 96-well cell culture plate and incubated at 37°C in 95% air and 5% CO2. After 24 hours, test compounds were added: starting at 10 mM (dissolved in DMSO), the compound was serially diluted 10-fold with DMSO to prepare a gradient stock solution. Complete medium containing 1% DMSO was prepared for further dilutions, temporarily referred to as "dilution buffer." Working solutions were prepared by diluting each stock solution with 99 volumes of dilution buffer: 1 μL of the 10 mM stock solution was added to 99 μL of dilution buffer, mixed, and finally 10 μL of the working solution was added to the plate seeded with cells. The final DMSO concentration in the cell culture medium was 0.2%, and the final concentration of the test compound ranged from 1 pM to 10 μM. The cells were incubated at 37°C for 3 days. The medium was aspirated and replaced with 90 μL / well of fresh complete medium. The test compound was then added according to the compound dilution method described above. On the 6th day, the CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega, catalog number G7573) was added to measure cell viability.
[0475] Cell viability was determined using the CellTiter-Glu kit, and the half-maximal inhibitory concentration of the compound on cell proliferation, i.e., the GI50 value, was calculated using the Prism program.
[0476] Figure 3A illustrates the inhibitory effect of exemplary compounds 2, 5, 6, 22, 31, and 34 of the present disclosure on the proliferation of MCF-7 cells after 6 days of administration. Figure 3B illustrates the inhibitory effect of exemplary compounds 35, 37, 44, 46, 47, and 48 of the present disclosure on the proliferation of MCF-7 cells after 6 days of administration. Figure 3C illustrates the inhibitory effect of exemplary compounds 88, 110, 119, 120, and 121 of the present disclosure on the proliferation of MCF-7 cells after 6 days of administration.
[0477] GI50 values (i.e., the concentration of the test compound that produces 50% inhibition of cell proliferation) were calculated for various compounds of the present disclosure and are shown in Table 2 below. A corresponds to a GI50 value below 10 nM; B corresponds to a GI50 value greater than 10 nM and less than 100 nM; and C corresponds to a GI50 value greater than 100 nM.
[0478] Table 2. GI50 values in MCF-7 cell line.
[0479] Test Example 4 Degradation activity of the disclosed compounds on ERα in T-47D cells
[0480] ERα-positive human breast cancer cells T-47D (ATCC, HTB-133) were cultured in RPMI 1640 medium (Thermo Fisher Scientific, Cat. No. 61870-036) containing 10% fetal bovine serum (Thermo Fisher Scientific, Cat. No. 10099141) and 10 μg / mL bovine insulin at 37°C in 95% air and 5% CO2 at 25 cm 2 or 75cm 2 Subculture 2 to 3 times a week in plastic tissue culture flasks.
[0481] The cells were plated at 1×10 6 Cells were seeded at a density of 1.8 mL / well in a 6-well cell culture plate and incubated at 37°C in 95% air and 5% CO2. Test compounds were added 24 hours later: starting at 10 mM (dissolved in DMSO), the compound was serially diluted three-fold in DMSO to prepare a gradient stock solution. Complete culture medium containing 1% DMSO was prepared for further dilutions, temporarily referred to as "dilution buffer." Working solutions were prepared by diluting each stock solution with 99 volumes of dilution buffer: 1 μL of the 10 mM stock solution was added to 99 μL of dilution buffer, mixed, and finally 10 μL of the working solution was added to the plate seeded with cells. The final DMSO concentration in the cell culture medium was 0.2%, and the final concentration of the test compound ranged from 0.1 nM to 1000 nM. The cells were incubated at 37°C for 4 hours.
[0482] Aspirate the culture medium, wash twice with pre-cooled PBS, add 1 mL of PBS to each well, collect the cells into an EP tube using a cell scraper, centrifuge at 4°C, 4000 rpm for 5 minutes, and aspirate the PBS. TM Total protein was extracted using animal cell / tissue total protein extraction reagent. Protein concentration was determined by the BCA assay. 30 μg of protein was mixed with 5× SDS-PAGE loading buffer, boiled for 10 minutes, and then added to the wells of a precast gel comb. The sample was run at a constant voltage of 80 V for 30 minutes. After the sample entered the separating gel, the sample was run at 120 V. A Bio-Rad Transblot "sandwich" was assembled: sponge-filter paper-gel-membrane-filter paper-sponge. Transfer was performed at 4°C at 0.3 amp for 1 hour. Blocking was performed with 5% nonfat dry milk for 1 hour at room temperature. Estrogen Receptor alpha Antibody (Thermo Fisher Scientific, Cat. No. MA5-14104) was then added with gentle shaking at 4°C overnight. Nonspecifically bound antibodies were removed from the membrane using TBST. A goat anti-mouse IgG-HRP secondary antibody was added and incubated at room temperature for 1 hour. ECL staining was performed. Protein degradation levels were calculated using grayscale.
[0483] Figure 4A illustrates the ERa degradation activity of exemplary compound 34 of the present disclosure in T-47D cell line 4 hours after administration. Figure 4B illustrates the ERa degradation activity of exemplary compound 35 of the present disclosure in T-47D cell line 4 hours after administration.
[0484] Test Example 5 Degradation Activity of the Disclosed Compounds on ERα in MCF-7 Cells Expressing ERα Y537S Mutant
[0485] MCF-7 cells expressing the ERαY537S mutant were constructed by lentiviral infection.
[0486] MCF-7 / ERαY537S cells were cultured at 1×10 6 Cells were seeded at a density of 1.8 mL / well in a 6-well cell culture plate and incubated at 37°C in 95% air and 5% CO2. Test compounds were added 24 hours later: starting at 10 mM (dissolved in DMSO), the compound was serially diluted three-fold with DMSO to prepare a gradient stock solution. Complete culture medium containing 1% DMSO was prepared for further dilutions, temporarily referred to as "dilution buffer." Working solutions were prepared by diluting each stock solution with 99 volumes of dilution buffer: 1 μL of the 10 mM stock solution was added to 99 μL of dilution buffer, mixed, and finally 10 μL of the working solution was added to the plate seeded with cells. The final DMSO concentration in the cell culture medium was 0.2%, and the final concentration of the test compound ranged from 0.1 nM to 1000 nM. The cells were incubated at 37°C for 4 and 6 hours, respectively.
[0487] Aspirate the culture medium, wash twice with pre-cooled PBS, add 1 mL of PBS to each well, collect the cells into an EP tube using a cell scraper, centrifuge at 4°C, 4000 rpm for 5 minutes, and aspirate the PBS. TM Total protein was extracted using animal cell / tissue total protein extraction reagent. Protein concentration was determined by the BCA assay. 30 μg of protein was mixed with 5× SDS-PAGE loading buffer, boiled for 10 minutes, and then added to the wells of a precast gel comb. The sample was run at a constant voltage of 80 V for 30 minutes. After the sample entered the separating gel, the sample was run at 120 V. A Bio-Rad Transblot "sandwich" was assembled: sponge-filter paper-gel-membrane-filter paper-sponge. Transfer was performed at 4°C at 0.3 amp for 1 hour. Blocking was performed with 5% nonfat dry milk for 1 hour at room temperature. Estrogen Receptor alpha Antibody (Thermo Fisher Scientific, Cat. No. MA5-14104) was then added with gentle shaking at 4°C overnight. Nonspecifically bound antibodies were removed from the membrane using TBST. A goat anti-mouse IgG-HRP secondary antibody was added and incubated at room temperature for 1 hour. ECL staining was performed. Protein degradation levels were calculated using grayscale.
[0488] Figure 5A illustrates the ERα degradation activity of exemplary compound 34 of the present disclosure in the MCF-7 / ERαY537S cell line 4 hours after administration. Figure 5B illustrates the ERα degradation activity of exemplary compound 35 of the present disclosure in the MCF-7 / ERαY537S cell line 4 hours after administration. Figure 5C illustrates the ERα degradation activity of exemplary compound 110 of the present disclosure in the MCF-7 / ERαY537S cell line 6 hours after administration. Figure 5D illustrates the ERα degradation activity of exemplary compound 120 of the present disclosure in the MCF-7 / ERαY537S cell line 6 hours after administration.
[0489] Test Example 6 Degradation Activity of the Disclosed Compounds on ERα in MCF-7 Cells Expressing ERαD538G Mutant
[0490] MCF-7 cells expressing the ERαD538G mutant were constructed by lentiviral infection.
[0491] MCF-7 / ERαD538G cells were cultured at 1×10 6 Cells were seeded at a density of 1.8 mL / well in a 6-well cell culture plate and incubated at 37°C in 95% air and 5% CO2. Test compounds were added 24 hours later: starting at 10 mM (dissolved in DMSO), the compound was serially diluted three-fold with DMSO to prepare a gradient stock solution. Complete culture medium containing 1% DMSO was prepared for further dilutions, temporarily referred to as "dilution buffer." Working solutions were prepared by diluting each stock solution with 99 volumes of dilution buffer: 1 μL of the 10 mM stock solution was added to 99 μL of dilution buffer, mixed, and finally 10 μL of the working solution was added to the plate seeded with cells. The final DMSO concentration in the cell culture medium was 0.2%, and the final concentration of the test compound ranged from 0.1 nM to 1000 nM. The cells were incubated at 37°C for 6 hours.
[0492] Aspirate the culture medium, wash twice with pre-cooled PBS, add 1 mL of PBS to each well, collect the cells into an EP tube with a cell scraper, centrifuge at 4°C, 4000 rpm for 5 minutes, and aspirate the PBS. TMTotal protein was extracted using animal cell / tissue total protein extraction reagent. Protein concentration was determined by the BCA assay. 30 μg of protein was mixed with 5× SDS-PAGE loading buffer, boiled for 10 minutes, and then added to the wells of a precast gel comb. The sample was run at a constant voltage of 80 V for 30 minutes. After the sample entered the separating gel, the sample was run at 120 V. A Bio-Rad Transblot "sandwich" was assembled: sponge-filter paper-gel-membrane-filter paper-sponge. Transfer was performed at 4°C at 0.3 amp for 1 hour. Blocking was performed with 5% nonfat dry milk for 1 hour at room temperature. Estrogen Receptor alpha Antibody (Thermo Fisher Scientific, Cat. No. MA5-14104) was then added with gentle shaking at 4°C overnight. Nonspecifically bound antibodies were removed from the membrane using TBST. A goat anti-mouse IgG-HRP secondary antibody was added and incubated at room temperature for 1 hour. ECL staining was performed. Protein degradation levels were calculated using grayscale.
[0493] Figure 6A illustrates the ERa degradation activity of exemplary compound 110 of the present disclosure in MCF-7 / ERαD538G cell line after 6 hours of administration. Figure 6B illustrates the ERa degradation activity of exemplary compound 120 of the present disclosure in MCF-7 / ERαD538G cell line after 6 hours of administration.
[0494] Test Example 7 Inhibitory Effect of the Compounds of the Present Application on the Proliferation of MCF-7 Cells Expressing ERα Y537S Mutant
[0495] MCF-7 / ERαY537S cells were cultured at 3×10 3 Cells were seeded at a density of 90 μL / well in a 96-well cell culture plate and incubated at 37°C in 95% air and 5% CO2. After 24 hours, test compounds were added: starting at 10 mM (dissolved in DMSO), the compound was serially diluted 10-fold with DMSO to prepare a gradient stock solution. Complete medium containing 1% DMSO was prepared for further dilutions, temporarily referred to as "dilution buffer." Working solutions were prepared by diluting each stock solution with 99 volumes of dilution buffer: 1 μL of the 10 mM stock solution was added to 99 μL of dilution buffer, mixed, and finally 10 μL of the working solution was added to the plate seeded with cells. The final DMSO concentration in the cell culture medium was 0.2%, and the final concentration of the test compound ranged from 1 pM to 10 μM. The cells were incubated at 37°C for 3 days. The medium was aspirated and replaced with 90 μL / well of fresh complete medium. The test compound was then added according to the compound dilution method described above. On the 6th day, the CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega, catalog number G7573) was added to measure cell viability.
[0496] Cell viability was determined using the CellTiter-Glu kit, and the half-maximal inhibitory concentration of the compound on cell proliferation, i.e., the GI50 value, was calculated using the Prism program.
[0497] Figure 7A illustrates the inhibitory effect of exemplary compound 110 of the present disclosure on the proliferation of MCF-7 / ERαY537S cells 6 days after administration. Figure 7B illustrates the inhibitory effect of exemplary compound 120 of the present disclosure on the proliferation of MCF-7 / ERαY537S cells 6 days after administration.
[0498] Test Example 8 Inhibitory Activity of the Disclosed Compounds on MCF-7 Xenograft Tumors Expressing ERα Y537S Mutant
[0499] MCF-7 / ERαY537S tumors that had been passaged for more than 3 generations but less than 10 generations in mice were inoculated subcutaneously in the right rib of female Balb / c nude mice with a mass of approximately 3 × 3 × 3 mm. When the tumor volume of the tumor-bearing mice reached approximately 200 mm 3 At about 14 days, the mice were randomly divided into 4 groups according to tumor volume and body weight: a solvent control group, an Example 1 mpk group, an Example 3 mpk group, and an Example 10 mpk group, with 7 mice in each group. The day of grouping was designated as D0, and oral administration began once a day for a total of 17 days, with the 17th day after administration designated as D17.
[0500] Tumor volume was measured twice weekly using a vernier caliper and mice were weighed using an electronic balance. The major and minor diameters of the tumors were measured. The volume was calculated using the formula: volume (TV) = 0.5 × major diameter × minor diameter 2. The T / C value was calculated based on tumor volume, where T is the mean relative tumor volume (RTV) of each test substance-treated group and C is the mean relative tumor volume (RTV) of the control group. RTV is the ratio of post-dose to pre-dose tumor volume. Tumor growth inhibition rate (TGITV) (%) = (1 - T / C) × 100%.
[0501] FIG8A illustrates the dose-dependent growth inhibition of compound 110 on MCF-7 / ERαY537S xenograft tumors in Balb / c nude mice.
[0502] FIG8B shows that compound 110 has no effect on the body weight of mice bearing MCF-7 / ERαY537S cell xenograft tumors.
[0503] FIG9A illustrates the dose-dependent growth inhibition ability of compound 120 on MCF-7 / ERαY537S xenograft tumors in Balb / c nude mice.
[0504] FIG9B shows that compound 120 has no effect on the body weight of mice bearing MCF-7 / ERαY537S cell xenograft tumors.
Claims
1. A PROTAC compound targeting an estrogen receptor represented by formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof: in, Indicates absence, substitution or unsubstituted Substituted or unsubstituted X 4 represents N or CRa, and the substituent is selected from halogen, hydroxyl, cyano, oxo, benzyl, substituted or unsubstituted amine, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl; When A does not exist, R 1 is selected from halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amine, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl, preferably R 1 Selected from -NH2 or -OH; X 1 N or CR 3 ; X 2 or X 3 Each independently selected from CH, CR 3 and N; R 2 , R 3 Each is independently selected from H, halogen, hydroxyl, cyano, oxo, benzyl, substituted or unsubstituted amine, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl; Ra is selected from H, halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amine, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl; L is selected from the following: E3L stands for ubiquitin ligase ligand.
2. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein E3L is selected from one of the following:
3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein the compound is represented by formula (II): in, R 4 Selected from halogen, hydroxy, cyano, oxo, benzyl, substituted or unsubstituted amine, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy and C1-C6 acyl.
4. The compound according to claim 3 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein: R 4 It is a halogen.
5. The compound according to claim 3 or its pharmaceutically acceptable salt, solvate, hydrate, or isomer, wherein the compound is represented by formula (III):
6. The compound according to claim 5, or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein the compound is represented by formula (IV):
7. The compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein: L is selected from the following:
8. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein: X 4 is N.
9. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein: X 4 is CRa, and Ra is selected from H, halogen and hydroxyl.
10. The compound according to claim 9 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein: Ra is H.
11. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein: X 1 CR 3 , R 3 is H, CH3O or F.
12. The compound according to claim 11 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein: R 3 For H.
13. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein: X 2 For CH.
14. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein: X 2 is N.
15. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein: X 3 For CH.
16. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein: R 2 For H.
17. The compound according to claim 2 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein E3L is 18. The compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, wherein the compound is selected from one of the following:
19. A pharmaceutical composition comprising the compound, pharmaceutically acceptable salt, solvate, hydrate, or isomer according to any one of claims 1 to 18, and a pharmaceutically acceptable carrier.
20. Use of the compound of any one of claims 1 to 18 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof or the pharmaceutical composition of claim 19 in treating a disease that is treated by degrading a target protein bound to a targeting ligand.
21. The use according to claim 20, wherein the disorder is selected from abnormal cell proliferation, cancer, immune disease, diabetes, cardiovascular disease, infectious disease and inflammatory disease.
22. The method of claim 21, wherein the cancer is selected from the group consisting of breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, endometriosis, fallopian tube tumors, ovarian tumors, leukemia, skin cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, bladder cancer, intestinal cancer, colon cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer, cervical cancer, pancreatic cancer, stomach cancer, lymphoma, non-Hodgkin's lymphoma, melanoma, myeloproliferative disease, sarcoma, vascular Sarcoma, peripheral neuroepithelioma, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, neuroblastoma, gangliocytoma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningiosarcoma, neurofibroma, schwannoma, thyroid cancer, Hodgkin's tumor, Wilms' tumor and teratocarcinoma; more preferably selected from breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, fallopian tube tumors and ovarian tumors.
23. The use according to claim 22, wherein the cancer is selected from breast cancer, endometrial cancer, ovarian cancer, cervical cancer, prostate cancer or endometriosis.
24. The use according to claim 21, wherein the infectious disease is selected from viral pneumonia, avian influenza, meningitis, gonorrhea or infection with HIV, HBV, HCV, HSV, HPV, RSV, CMV, Ebola virus, flavivirus, rotavirus, influenza, coronavirus, EBV, drug-resistant virus, RNA virus, DNA virus, adenovirus, poxvirus, picornavirus, togavirus, orthomyxovirus, retrovirus, hepadnavirus, Gram-negative bacteria, Gram-positive bacteria, atypical bacteria, Staphylococcus, Streptococcus, Escherichia coli, Salmonella, Helicobacter pylori, Chlamydiaceae, Mycoplasmaceae, fungi, protozoa, intestinal worms, helminths, prions or parasites.
25. Use of the compound according to any one of claims 1 to 18 or its pharmaceutically acceptable salt, solvate, hydrate, or isomer or the pharmaceutical composition according to claim 19 in the preparation of a medicament for treating a disease treated by degrading a target protein bound to a targeting ligand.
26. The use according to claim 24, wherein the disorder is selected from abnormal cell proliferation, cancer, immune disease, diabetes, cardiovascular disease, infectious disease and inflammatory disease.
27. The method of claim 26, wherein the cancer is selected from the group consisting of breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, endometriosis, fallopian tube tumors, ovarian tumors, leukemia, skin cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, bladder cancer, intestinal cancer, colon cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer, cervical cancer, pancreatic cancer, stomach cancer, lymphoma, non-Hodgkin's lymphoma, melanoma, myeloproliferative disease, sarcoma, vascular Sarcoma, peripheral neuroepithelioma, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, neuroblastoma, gangliocytoma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningiosarcoma, neurofibroma, schwannoma, thyroid cancer, Hodgkin's tumor, Wilms' tumor and teratocarcinoma; more preferably selected from breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, fallopian tube tumors and ovarian tumors.
28. The use according to claim 27, wherein the cancer is selected from breast cancer, endometrial cancer, ovarian cancer, cervical cancer, prostate cancer or endometriosis.
29. The method of claim 26, wherein the infectious disease is selected from viral pneumonia, avian influenza, meningitis, gonorrhea, or infection with HIV, HBV, HCV, HSV, HPV, RSV, CMV, Ebola virus, flavivirus, rotavirus, influenza, coronavirus, EBV, drug-resistant virus, RNA virus, DNA virus, adenovirus, poxvirus, picornavirus, togavirus, orthomyxovirus, retrovirus, hepadnavirus, Gram-negative bacteria, Gram-positive bacteria, atypical bacteria, Staphylococcus, Streptococcus, Escherichia coli, Salmonella, Helicobacter pylori, Chlamydiaceae, Mycoplasmaceae, fungi, protozoa, intestinal worms, helminths, prions or parasites.
30. A method for treating a condition in a subject by degrading a target protein bound to a targeting ligand, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt, solvate, hydrate, or isomer thereof, or a pharmaceutical composition according to claim 19.
31. The method of claim 30, wherein the disorder is selected from abnormal cell proliferation, cancer, immune disease, diabetes, cardiovascular disease, infectious disease, and inflammatory disease.
32. The method of claim 31, wherein the cancer is selected from the group consisting of breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, endometriosis, fallopian tube tumors, ovarian tumors, leukemia, skin cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, bladder cancer, intestinal cancer, colon cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer, cervical cancer, pancreatic cancer, stomach cancer, lymphoma, non-Hodgkin's lymphoma, melanoma, myeloproliferative disease, sarcoma, vascular Sarcoma, peripheral neuroepithelioma, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, neuroblastoma, gangliocytoma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningiosarcoma, neurofibroma, schwannoma, thyroid cancer, Hodgkin's tumor, Wilms' tumor and teratocarcinoma; more preferably selected from breast cancer, endometrial cancer, uterine cancer, testicular cancer, cervical cancer, prostate cancer, ovarian cancer, fallopian tube tumors and ovarian tumors.
33. The method of claim 32, wherein the cancer is selected from breast cancer, endometrial cancer, ovarian cancer, cervical cancer, prostate cancer, or endometriosis.
34. The method of claim 31, wherein the infectious disease is selected from viral pneumonia, avian influenza, meningitis, gonorrhea, or infection with HIV, HBV, HCV, HSV, HPV, RSV, CMV, Ebola virus, flavivirus, trachea virus, rotavirus, influenza, coronavirus, EBV, drug-resistant virus, RNA virus, DNA virus, adenovirus, poxvirus, picornavirus, togavirus, orthomyxovirus, retrovirus, hepadnavirus, Gram-negative bacteria, Gram-positive bacteria, atypical bacteria, Staphylococcus, Streptococcus, Escherichia coli, Salmonella, Helicobacter pylori, Chlamydiaceae, Mycoplasmaceae, fungi, protozoa, intestinal worms, helminths, prions, or parasites.
Citation Information
Patent Citations
Compound capable of degrading BTK kinase as well as preparation method and pharmaceutical application of compound
CN112812100A
Preparation of targeted GSK3 alpha / beta degradation agent and medical application thereof
CN113248473A
Systems and methods for managing practice airspace
US20190019419A1
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
US20190151295A1
Acrylic acid derivative, preparation method therefore and medical application of acrylic acid derivative
CN106518768A
